Schedule 1Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

(section 4)

 

Part 2 – Table 1

Column 1

Column 2

Ingredient Name

Column 3

Purpose of the ingredient in the medicine

Column 4

Specific requirements(s) applying to the ingredient in Column 2

3600

P-ALPHA-DIMETHYL STYRENE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3601

P-ANISIC ACID

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 0.3%.

 

3602

PADIMATE O

A

Only for use as an active ingredient in sunscreens for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 8%.

When used in primary sunscreen products and listed in the Register on or after 1 January 2018, the medicine must have the following statements on the medicine label:

- (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and

- (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).

When used in primary sunscreen products and listed in the Register before 1 January 2018, the medicine requires the following statements on the medicine label if supplied after 1 July 2019:

- (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and

- (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).

 

 

3603

PADINA PAVONICA THALLUS PHYTOSTEROLS

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.01%.

 

3604

PAEONIA LACTIFLORA

A, E, H

 

3605

PAEONIA OBOVATA

A, H

 

3606

PAEONIA SUFFRUTICOSA

A, E, H

 

3607

PAEONIA VEITCHII

A, H

 

3608

PALIURUS SPINA-CHRISTI

A, H

 

3609

PALLADIUM

H

Only for use as an active homoeopathic ingredient.

 

3610

PALM FRUIT OIL

A, E, H

 

3611

PALM GLYCERIDES

E

 

3612

PALM KERNEL OIL

A, E, H

 

3613

PALM TOCOTRIENOLS COMPLEX

A, H

 

3614

PALMARIA PALMATA

A, H

 

3615

PALMAROSA OIL

A, E, H

 

3616

PALMITIC ACID

E

 

3617

PALMITOLEIC ACID-RICH FATTY ACID ETHYL ESTERS

A

 

3618

PALMITOYL DIPEPTIDE-7

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.002%.

 

3619

PALMITOYL HYDROXYPROPYLTRIMONIUM AMYLOPECTIN/GLYCERIN CROSSPOLYMER

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.01%

 

3620

PALMITOYL OLIGOPEPTIDE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.002%.

 

3621

PALMITOYL PENTAPEPTIDE-3

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.0005%.

 

3622

PALMITOYL TETRAPEPTIDE-3

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.001%.

 

3623

PANAX GINSENG

A, E, H

 

3624

PANAX JAPONICUS

A, H

 

3625

PANAX NOTOGINSENG

A, H

 

3626

PANAX PSEUDOGINSENG

A, H

 

3627

PANAX QUINQUEFOLIUS

A, H

 

3628

PANICUM MILIACEUM

A, H

 

3629

PANTETHINE

E

Only for use in topical medicines for dermal application.

 

3630

PANTHENOL

A, E

 

3631

PANTHENYL ETHYL ETHER

E

Only for use in topical medicines for dermal application.

 

3632

PANTOLACTONE

E

 

3633

PANTOTHENIC ACID

A, E

When used topically, the concentration in the medicine must be no more than 0.1%.

 

3634

PANTOTHENIC ACID POLYPEPTIDE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.1%.

 

3635

PAPAIN

A, E

 

3636

PAPER

E

Only for use in topical medicines for dermal application.

 

3637

PAPRIKA OLEORESIN

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

3638

PARA-CRESOL

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3639

PARA-CRESYL ACETATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3640

PARA-CRESYL ISOBUTYRATE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3641

PARA-CRESYL PHENYLACETATE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3642

PARA-CYMENE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3643

PARA-ETHOXYBENZALDEHYDE

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

3644

PARA-ETHYLPHENOL

E

Permitted for use only in combination with other permitted ingredients as part of a flavour proprietary excipient formulation.

The maximum recommended daily dose must contain no more than 0.12 mg of para-ethylphenol.

The total flavour proprietary excipient formulation in a medicine must be no more than 5%.

 

3645

PARA-HYDROXY BENZALACETONE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3646

PARA-HYDROXYBENZOIC ACID

E

 

3647

PARA-MENTHA-8-THIOL-3-ONE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3648

PARA-METHYL ACETOPHENONE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3649

PARA-METHYL ANISOLE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3650

PARA-METHYL DIMETHYLBENZYL CARBINOL

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3651

PARA-PROPYL ANISOLE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3652

PARA-TERT-BUTYLCYCLOHEXYL ACETATE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3653

PARA-TERT-BUTYLPHENYL-ALPHA-METHYLHYDROCINNAMIC ALDEHYDE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3654

PARA-TOLUALDEHYDE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3655

PARA-TOLYL ACETALDEHYDE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3656

PARAMERIA LAEVIGATA

A, H

 

3657

PARIETARIA JUDAICA

A, H

 

3658

PARIS POLYPHYLLA

A, H

 

3659

PARIS QUADRIFOLIA

A, H

 

3660

PARSLEY

E, H

 

3661

PARSLEY HERB DRY

A, E, H

 

3662

PARSLEY HERB OIL

A, E, H

 

3663

PARSLEY HERB POWDER

A, E, H

 

3664

PARSLEY SEED OIL

A, E, H

 

3665

PARTHENOCISSUS TRICUSPIDATA

A, H

 

3666

PARTIALLY HYDROGENATED SOYA OIL

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in the medicine must be no more than 5%.

 

3667

PARTIALLY REFINED PORPHYRA YEZOENSIS CYTOPLASM EXTRACT

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.00002%.

 

3668

PASPALUM NOTATUM

A, H

 

3669

PASSIFLORA CAERULEA

A, H

 

3670

PASSIFLORA EDULIS

E

 

3671

PASSIFLORA HERB DRY

A, H

 

3672

PASSIFLORA INCARNATA

A, E, H

 

3673

PATCHOULI OIL

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3674

PATENT BLUE V

E

Permitted for use only as a colour for oral and topical use.

 

3675

PATENT BLUE V ALUMINIUM LAKE

E

Permitted for use only as a colour for oral and topical use.

 

3676

PATRINIA SCABIOSIFOLIA

A, H

 

3677

PATRINIA VILLOSA

A, H

 

3678

PAULLINIA CUPANA

A, E, H

Caffeine is a mandatory component of Paullinia cupana when used for oral ingestion.

When the route of administration is oral or sublingual and the medicine provides a maximum recommended daily dose of more than 1 mg but no more than 10 mg of caffeine in the medicine requires the following warning statement on the medicine label:

- (CAFFR) ‘The recommended dose of this medicine provides small amounts of caffeine.’

When the route of administration is oral or sublingual and the medicine provides a maximum recommended daily dose of more than 10 mg of caffeine in the medicine requires the following warning statement on the medicine label:

- (CAFF) ‘Contains caffeine [state quantity per dosage unit or per mL or per gram of product]’.

 

3679

PAULLINIA PINNATA

A, H

 

3680

PAWPAW

E

 

3681

PEA

E

 

3682

PEA STARCH

E

 

3683

PEACH

E

 

3684

PEANUT

E

The medicine requires the following warning statement on the medicine label:

- (PEANUT) ‘Contains Peanut’ (or words to that effect).

 

 

3685

PEAR

E

 

3686

PECAN

E

 

3687

PECTIN

A, E

 

3688

PEG-10 DIMETICONE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or damaged skin.

The concentration in the medicine must be no more than 4.0%.

 

3689

PEG-10 SOYA STEROL

E

Only for use in topical medicines for dermal application.

 

3690

PEG-100 STEARATE

E

Only for use in topical medicines for dermal application.

 

3691

PEG-12 DILAURATE

E

 

3692

PEG-12 DIMETICONE/PPG-20 CROSSPOLYMER

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 2%.

 

3693

PEG-120 METHYL GLUCOSE DIOLEATE

E

Only for use in topical medicines for dermal application.

 

3694

PEG-120 STEARATE

E

Only for use in topical medicines for dermal application.

 

3695

PEG-15 COCAMINE

E

Only for use in topical medicines for dermal application.

 

3696

PEG-150 DISTEARATE

E

Only for use in topical medicines for dermal application.

 

3697

PEG-20 ALMOND GLYCERIDES

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.5%.

 

3698

PEG-20 METHYL GLUCOSE DISTEARATE

E

Only for use in topical medicines for dermal application.

 

3699

PEG-20 METHYL GLUCOSE SESQUISTEARATE

E

Only for use in topical medicines for dermal application.

 

3700

PEG-20 SORBITAN ISOSTEARATE

E

Only for use in topical medicines for dermal application.

 

3701

PEG-20 STEARATE

E

Only for use in topical medicines for dermal application.

 

3702

PEG-25 PABA

A

Only for use as an active ingredient in sunscreens for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 10%.

When used in primary sunscreen products and listed in the Register on or after 1 January 2018, the medicine must have the following statements on the medicine label:

- (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and

- (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).

When used in primary sunscreen products and listed in the Register before 1 January 2018, the medicine requires the following statements on the medicine label if supplied after 1 July 2019:

- (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and

- (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).

 

3703

PEG-30 DIPOLYHYDROXYSTEARATE

E

Only for use in topical medicines for dermal application.

 

3704

PEG-30 STEARATE

E

Only for use in topical medicines for dermal application.

 

3705

PEG-35 CASTOR OIL

E

 

3706

PEG-4 DILAURATE

E

Only for use in topical medicines for dermal application.

 

3707

PEG-4 LAURATE

E

Only for use in topical medicines for dermal application.

Dioxane and Ethylene oxide are mandatory components of PEG-4 laurate.

The concentration of Dioxane in the medicine must be no more than 10 mg/kg or 10 mg/L or 0.001%.

The concentration of Ethylene oxide in the medicine must be no more than 1 mg/kg or 1 mg/L or 0.0001%.

 

3708

PEG-4 STEARATE

E

Only for use in topical medicines for dermal application.

 

3709

PEG-40 CASTOR OIL

E

 

3710

PEG-40 HYDROGENATED CASTOR OIL

E

 

3711

PEG-40 SORBITAN DIISOSTEARATE

E

Only for use in topical medicines for dermal application.

Dioxane and Ethylene oxide are mandatory components of PEG-40 sorbitan diisostearate.

The concentration of Dioxane in the medicine must be no more than 10 mg/kg or 10 mg/L or 0.001%.

The concentration of Ethylene oxide in the medicine must be no more than 1 mg/kg or 1 mg/L or 0.0001%.

 

3712

PEG-40 STEARATE

E

Only for use in topical medicines for dermal application.

 

3713

PEG-45/DODECYL GLYCOL COPOLYMER

E

Only for use in topical medicines for dermal application.

 

3714

PEG-5 GLYCERYL STEARATE

E

Only for use in topical medicines for dermal application.

 

3715

PEG-50 STEARATE

E

Only for use in topical medicines for dermal application.

 

3716

PEG-55 PROPYLENE GLYCOL OLEATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.6%.

 

3717

PEG-6 LAURAMIDE

E

Only for use in topical medicines for dermal application.

 

3718

PEG-60 ALMOND GLYCERIDES

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration when used in medicines applied directly to the skin must be no more than 10%.

The concentration when used in bath oil medicines must be no more than 30%.

 

3719

PEG-60 GLYCERYL ISOSTEARATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 2%.

 

3720

PEG-60 HYDROGENATED CASTOR OIL

E

Only for use in topical medicines for dermal application.

 

3721

PEG-7 COCAMIDE

E

Only for use in topical medicines for dermal application.

 

3722

PEG-7 GLYCERYL COCOATE

E

Only for use in topical medicines for dermal application.

 

3723

PEG-7 HYDROGENATED CASTOR OIL

E

Only for use in topical medicines for dermal application.

 

3724

PEG-75 LANOLIN

E

Only for use in topical medicines for dermal application.

 

3725

PEG-75 STEARATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 1.5%.

 

3726

PEG-8 CETYL DIMETHICONE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.0005%.

 

3727

PEG-8 DILAURATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 4%.

 

3728

PEG-8 DISTEARATE

E

Only for use in topical medicines for dermal application.

 

3729

PEG-8 LAURATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 4%.

The levels of possible impurities such as ethylene oxide (and related material) must be kept below the level of detection.

 

3730

PEG-8 PROPYLENE GLYCOL COCOATE

E

 

3731

PEG-8 STEARATE

E

Only for use in topical medicines for dermal application.

 

3732

PEG-9 POLYDIMETHYLSILOXYETHYL DIMETICONE

E

Only for use in topical medicines for dermal application and not to be included in medicines for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 3.5%.

 

3733

PEG/PPG-14/7 DIMETHYL ETHER

E

Only for use in topical medicines for dermal application and not to be included in medicines for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 7%.

 

3734

PEG/PPG-18/18 DIMETHICONE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 5%.

 

3735

PELARGONIUM GRAVEOLENS

A, E, H

 

3736

PELLITORINE

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

3737

PELTIGERA CANINA

A, H

 

3738

PENICILLIUM EXPANSUM

A, H

 

3739

PENNYROYAL OIL

E

D-Pulegone/Pulegone is a mandatory component of Pennyroyal Oil.

The concentration of D Pulegone/ Pulegone in the medicine must be no more than 4%.

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in the medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in the medicine must be no more than 1%.

When the medicine is for a use other than topical, the maximum recommended daily dose must be no more than 50 mg of Pennyroyal Oil.

 

3740

PENTAERYTHRITYL TETRA-DI-T-BUTYL HYDROXYHYDROCINNAMATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.018%

 

3741

PENTAERYTHRITYL TETRAISOSTEARATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 61%.

 

3742

PENTAERYTHRITYL TETRALAURATE

E

Only for use in topical medicines for dermal application.

The concentration in the medicine must be no more than 80%.

 

3743

PENTAMETHYLHEPTENONE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3744

PENTANE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3745

PENTASODIUM ETHYLENEDIAMINE TETRAMETHYLENE PHOSPHONATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.1%.

 

3746

PENTYLENE GLYCOL

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 5%.

 

3747

PEPPER BLACK

E, H

 

3748

PEPPER OIL TERPENELESS

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3749

PEPPER WHITE

E, H

 

3750

PEPPERMINT AMERICAN EXT.

E

Menthol is a mandatory component of peppermint american ext.

When the medicine is for topical use:

a) the medicine must not be intended for use in the eye or on damaged skin;

b) the maximum concentration of menthol must not exceed 5%; and

c) the following warning statements are required on the medicine label:

- (SKTEST) If you have sensitive skin, test this product on a small area of skin before applying it to a large area;

- (IRRIT) If irritation develops, discontinue use; and

- (EYE) Avoid contact with eyes (or words to that effect).

When the medicine is for internal use, the maximum recommended daily dose must not contain more than 1 gram of menthol.

 

3751

PEPPERMINT LEAF DRY

A, E, H

When the ingredient is included in a medicine that is listed in the Register:

- on or after 1 July 2018, the medicine must comply with all requirements under (a)-(c);

- before 1 July 2018 and supplied on or after 1 January 2020, the medicine must comply with all requirements under (a)-(c); or

- before 1 July 2018 and supplied before 1 January 2020, the medicine may comply with requirements under (a)-(c).

a) Menthol is a mandatory component of peppermint leaf dry.

b) When the medicine is for topical use:

(i) the medicine must not be intended for use in the eye or on damaged skin;

(ii) the maximum concentration of menthol must not exceed 5%; and

(iii) the following warning statements are required on the medicine label:

- (SKTEST) If you have sensitive skin, test this product on a small area of skin before applying it to a large area;

- (IRRIT) If irritation develops, discontinue use; and

- (EYE) Avoid contact with eyes (or words to that effect).

c) When the medicine is for internal use, the maximum recommended daily dose must not contain more than 1 gram of menthol.

 

3752

PEPPERMINT LEAF POWDER

A, E, H

When the ingredient is included in a medicine that is listed in the Register:

- on or after 1 July 2018, the medicine must comply with all requirements under (a)-(c);

- before 1 July 2018 and supplied on or after 1 January 2020, the medicine must comply with all requirements under (a)-(c); or

- before 1 July 2018 and supplied before 1 January 2020, the medicine may comply with requirements under (a)-(c).

a) Menthol is a mandatory component of peppermint leaf powder.

b) When the medicine is for topical use:

(i) the medicine must not be intended for use in the eye or on damaged skin;

(ii) the maximum concentration of menthol must not exceed 5%; and

(iii) the following warning statements are required on the medicine label:

- (SKTEST) If you have sensitive skin, test this product on a small area of skin before applying it to a large area;

- (IRRIT) If irritation develops, discontinue use; and

- (EYE) Avoid contact with eyes (or words to that effect).

c) When the medicine is for internal use, the maximum recommended daily dose must not contain more than 1 gram of menthol.

 

3753

PEPPERMINT OIL

A, E, H

When the ingredient is included in a medicine that is listed in the Register:

- on or after 1 July 2018, the medicine must comply with all requirements under (a)-(c);

- before 1 July 2018, and supplied on or after 1 January 2020 the medicine must comply with all requirements under (a)-(c); or

- before 1 July 2018 and supplied before 1 January 2020, the medicine may comply with requirements under (a)-(c).

a) Menthol is a mandatory component of peppermint oil.

b) When the medicine is for topical use:

(i) the medicine must not be intended for use in the eye or on damaged skin;

(ii) the maximum concentration of menthol must not exceed 5%; and

(iii) the following warning statements are required on the medicine label:

- (SKTEST) If you have sensitive skin, test this product on a small area of skin before applying it to a large area;

- (IRRIT) If irritation develops, discontinue use; and

- (EYE) Avoid contact with eyes (or words to that effect).

c) When the medicine is for internal use, the maximum recommended daily dose must not contain more than 1 gram of menthol.

 

3754

PEPPERMINT OIL TERPENELESS

E

Permitted for use only in combination with other permitted ingredients as a flavour proprietary excipient formulation or fragrance proprietary excipient formulation.

The total flavour proprietary excipient formulation in a medicine must be no more than 5%.

The total fragrance proprietary excipient formulation in a medicine must be no more 1%.

Menthol is a mandatory component of peppermint oil terpeneless.

When the medicine is for topical use:

a) the medicine must not be intended for use in the eye or on damaged skin;

b) the maximum concentration of menthol must not exceed 5%; and

c) the following warning statements are required on the medicine label:

- (SKTEST) If you have sensitive skin, test this product on a small area of skin before applying it to a large area;

- (IRRIT) If irritation develops, discontinue use; and

- (EYE) Avoid contact with eyes (or words to that effect).

When the medicine is for internal use, the maximum recommended daily dose must not contain more than 1 gram of menthol.

 

3755

PEPPERMINT OIL TERPENES AND TERPENOIDS

E

Permitted for use only in combination with other permitted ingredients as a flavour proprietary excipient formulation.

The total flavour proprietary excipient formulation in a medicine must be no more than 5%.

Menthol is a mandatory component of peppermint oil terpenes and terpenoids.

When the medicine is for topical use:

a) the medicine must not be intended for use in the eye or on damaged skin;

b) the maximum concentration of menthol must not exceed 5%; and

c) the following warning statements are required on the medicine label:

- (SKTEST) If you have sensitive skin, test this product on a small area of skin before applying it to a large area;

- (IRRIT) If irritation develops, discontinue use; and

- (EYE) Avoid contact with eyes (or words to that effect).

When the medicine is for internal use, the maximum recommended daily dose must not contain more than 1 gram of menthol.

 

3756

PERFLUOROPOLYMETHYLISOPROPYL ETHER

E

Only for use in topical medicines for dermal application.

 

3757

PERHYDRO-3,6-DIMETHYL-BENZO [B] FURAN-2-ONE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3758

PERILLA FRUTESCENS

A, E, H

Rosmarinic acid and vicenin-2 are only permitted for use if the plant part of Perilla frutescens is leaf.

 

3759

PERILLALDEHYDE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3760

PERLITE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 2%.

 

3761

PERMETHRIN

E

The concentration of in the medicine must be no more than 2%.

 

3762

PERSEA AMERICANA

A, E, H

 

3763

PERSIC OIL

A, E, H

Amygdalin and Hydrocyanic acid are mandatory components of Persic oil.

The concentration of amygdalin in the medicine must be no more than 0%.

The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.

 

3764

PERSICARIA CHINENSIS

A, H

 

3765

PERSICARIA TINCTORIA

A, H

 

3766

PERSIMMON

E

 

3767

PERU BALSAM

A, E, H

 

3768

PERU BALSAM OIL

A, E, H

 

3769

PETITGRAIN MANDARIN OIL

E

Permitted for use only in combination with other permitted ingredients as a flavour

The final concentration of the oil in the flavour does not exceed 30%

If used in a flavour the total flavour concentration in a medicine must be no more than 5%

 

3770

PETITGRAIN OIL

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3771

PETITGRAIN OIL CITRONNIER

E

Permitted for use only in combination with other permitted ingredients as part of a fragrance proprietary excipient formulation.

When included in a medicine for use on the lips the concentration of petitgrain oil citronnier must be no more than 0.1%.

When included in dermal creams for infant use the concentration of petitgrain oil citronnier must be no more than 0.5%

The total fragrance proprietary excipient formulation in a medicine must be no more than 1%.

 

 

3772

PETITGRAIN OIL PARAGUAY

A, E, H

When used internally, oxedrine is a mandatory component of petitgrain oil paraguay.

The quantity of oxedrine in the maximum recommended daily dose must be no more than 30 milligrams.

 

 

3773

PETITGRAIN OIL TERPENELESS

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3774

PETROSELINUM CRISPUM

A, E, H

 

3775

PEUCEDANUM PRAERUPTORUM

A, E, H

 

3776

PEUMUS BOLDUS

A, H

Volatile oil components (of Peumus boldus) is a mandatory component.

The maximum recommended daily dose must be no more than 100 mg of volatile oil components (of Peumus boldus).

 

3777

PHALARIS ARUNDINACEA

A, H

 

3778

PHALARIS CANARIENSIS

A, H

 

3779

PHASEOLUS COCCINEUS

A, H

 

3780

PHASEOLUS VULGARIS

A, H

 

3781

PHELLINUS ROBINIAE

A, E, H

 

3782

PHELLODENDRON AMURENSE

A, E, H

 

3783

PHELLODENDRON CHINENSE

A, H

 

3784

PHENACETIN

E

Only for use in topical medicines for dermal application.

The concentration in the medicine must be no more than 0.1%.

 

3785

PHENETHYL 2-METHYLBUTYRATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3786

PHENETHYL ACETATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3787

PHENETHYL ALCOHOL

E

Permitted for use only:

a) in topical medicines for dermal application; and

b) for internal use in combination with other permitted ingredients as part of a flavour proprietary excipient formulation.

The total flavour proprietary excipient formulation concentration in a medicine must be no more than 5%.

 

 

3788

PHENETHYL BENZOATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 6%.

 

3789

PHENETHYL DIMETHICONE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.2%

 

3790

PHENETHYL ISOAMYL ETHER

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used as in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3791

PHENETHYL ISOBUTYRATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3792

PHENETHYL ISOVALERATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3793

PHENETHYL PHENYLACETATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3794

PHENETHYL SALICYLATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3795

PHENOL

E

Only for use in topical medicines for dermal application.

The concentration of phenol in the medicine must be no more than 1%.

 

3796

PHENOXYACETALDEHYDE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3797

PHENOXYETHANOL

E

Only for use in topical medicines for dermal application.

The concentration of phenoxyethanol in the preparation must not exceed 15%.

 

 

3798

PHENOXYETHYL ISOBUTYRATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3799

PHENOXYETHYLPARABEN

E

Only for use in topical medicines for dermal application.

 

3800

PHENYL DIMETHICONE

E

Only for use in topical medicines for dermal application.

 

3801

PHENYL TRIMETHICONE

E

Only for use in topical medicines for dermal application.

 

3802

PHENYLACETALDEHYDE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3803

PHENYLACETALDEHYDE DIMETHYL ACETAL

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3804

PHENYLACETALDEHYDE GLYCERYLACETAL

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3805

PHENYLACETIC ACID

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3806

PHENYLALANINE

A, E

When for oral ingestion the medicine requires the following warning statement on the medicine label:

- (PKU) 'Phenylketonurics are warned that this medicine contains phenylalanine' (or words to that effect).

When the medicine contains more than 500mg in the maximum recommended daily dose it requires the following warning statement on the medicine label:

- (PREGNT2) 'Do not use if pregnant or likely to become pregnant'.

 

3807

PHENYLBENZIMIDAZOLE SULFONIC ACID

A

Only for use as an active ingredient in sunscreens for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 4%.

When used in primary sunscreen products and listed in the Register on or after 1 January 2018, the medicine must have the following statements on the medicine label:

- (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and

- (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).

When used in primary sunscreen products and listed in the Register before 1 January 2018, the medicine requires the following statements on the medicine label if supplied after 1 July 2019:

- (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and

- (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).

 

 

3808

PHENYLETHYL BUTYRATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

3809

PHENYLETHYL CAPROATE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3810

PHENYLETHYL CAPRYLATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3811

PHENYLETHYL CINNAMATE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3812

PHENYLETHYL FORMATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3813

PHENYLETHYL METHYLETHYL CARBINOL

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

3814

PHENYLETHYL PROPIONATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3815

PHENYLETHYL TIGLATE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3816

PHENYLISOPROPYL DIMETICONE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 5%.

 

3817

PHENYLPROPANOL

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.16%.

 

3818

PHLEUM PRATENSE

A, H

 

3819

PHLOXINE B

E

Permitted for use only as a colour for oral and topical use.

 

3820

PHLOXINE B ALUMINIUM LAKE

E

Permitted for use only as a colour for oral and topical use.

 

3821

PHOENIX DACTYLIFERA

A, E, H

 

3822

PHOSPHATIDYL CHOLINE

E

 

3823

PHOSPHOLIPIDS

E

Only for use in topical medicines for dermal application and not intended for use in the eye.

The concentration in the medicine must be no more than 20%.

 

3824

PHOSPHORIC ACID

E, H

The concentration in liquid medicines must be no more than 15%.

 

 

3825

PHOSPHORUS

H

Only for use as an active homoeopathic ingredient. 

 

3826

PHOTINIA SERRULATA

A, H

 

3827

PHRAGMITES AUSTRALIS

A, H

 

3828

PHYLLANTHUS AMARUS

A, H

 

3829

PHYLLANTHUS EMBLICA

A, E, H

When used as an excipient, only for use in topical medicines for dermal application.

When ascorbic acid is claimed as a component the plant part is restricted to fruit.

 

3830

PHYLLOSTACHYS NIGRA

A, E, H

 

3831

PHYSALIS ALKEKENGI

A, H

 

3832

PHYSALIS PUBESCENS

A, H

 

3833

PHYTANTRIOL

E

Only for use in topical medicines for dermal application.

The concentration in the medicine must be no more than 0.5%.

 

3834

PHYTOL

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3835

PHYTOLACCA AMERICANA

A, H

The maximum recommended daily dose of the medicine must contain no more than 1mg of the equivalent dry herb.

 

3836

PHYTOMENADIONE

A, E

 

3837

PHYTOSPHINGOSINE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.1%.

 

3838

PHYTOSTERYL/OCTYLDODECYL LAUROYL GLUTAMATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.1%.

 

3839

PICEA ABIES

A, H

 

3840

PICEA MARIANA

A, H

 

3841

PICRASMA EXCELSA

A, E, H

 

3842

PICRORRHIZA KURROA

A, E, H

 

3843

PIGMENT BLUE 15

E

Permitted for use only as a colour for topical and dental use.

The concentration in medicine must be no more than 0.003%.

 

3844

PIGMENT BLUE 15:1

E

Permitted for use only as a colour for topical use.

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.21%.

 

3845

PIGMENT GREEN 7

E

Permitted for use only as a colour for topical and dental use.

When for dental use, the concentration in the medicine must be no more than 0.003%.

When for topical use, the concentration in the medicine must be no more than 0.17%.

 

3846

PIGMENT RED 4

E

Permitted for use only as a colour for topical use.

 

3847

PIGMENT RED 53

E

Permitted for use only as a colour for topical use.

 

3848

PIGMENT RED 57

E

Permitted for use only as a colour for topical use.

 

3849

PIGMENT RED 57 ALUMINIUM LAKE

E

Permitted for use only as a colour for topical use.

 

3850

PIGMENT RED 57 BARIUM LAKE

E

Permitted for excipient use as a colour in topical medicines for dermal application.

Not to be included in medicines intended for use in the eye.

 

3851

PIGMENT RED 63

E

Permitted for use only as a colour for topical use.

 

 

3852

PIGMENT WHITE 26

E

Permitted for use only as a colour for topical use.

 

3853

PIGMENT YELLOW 12

E

Permitted for use only as a colour for topical use.

 

3854

PILOCARPUS JABORANDI

A, H

Pilocarpine is a mandatory component of Pilocarpus  jaborandi.

The concentration of pilocarpine in the medicine must be no more than 0.025%.

 

3855

PILOCARPUS MICROPHYLLUS

A, H

Pilocarpine is a mandatory component of Pilocarpus microphyllus.

The concentration of pilocarpine in the medicine must be no more than 0.025%.

 

3856

PILOCARPUS PINNATIFOLIUS

A, H

Pilocarpine is a mandatory component of Pilocarpus pinnatifolius.

The concentration of pilocarpine in the medicine must be no more than 0.025%.

 

3857

PIMENTA FRUIT OIL

A, E, H

 

3858

PIMENTA LEAF OIL

A, E, H

 

3859

PIMENTA OFFICINALIS

A, E, H

 

3860

PIMENTA RACEMOSA

A, E, H

When the plant preparation for Pimenta racemosa is an oil and the concentration of this oil in the medicine is more than 25%, the nominal capacity of the container must be no more than 25 mL.

When the plant preparation for Pimenta racemosa is an oil, the concentration of this oil in the medicine is more than 25%, and  the nominal capacity of the container is more than 15 mL, a restricted flow insert must be fitted on the container.

When the plant preparation for Pimenta racemosa is an oil, the concentration of this oil in the medicine is more than 25%, and the nominal capacity of the container is more than 15 mL but no more than 25 mL, a child resistant closure and restricted flow insert must be fitted on the container.

The medicine requires the following warning statements on the medicine label:

- (CHILD) 'Keep out of reach of children' (or word to that effect)

- (NTAKEN) 'Not to be taken'.

 

3861

PIMPINELLA ANISUM

A, E, H

When the plant preparation for Pimpinella anisum is an oil or distillate and the concentration of this oil or distillate in the medicine is more than 50%: a) the nominal capacity of the container must be no more than 50 millilitres; and b) a restricted flow insert is must be fitted on the container; and c) the medicine requires the following warning statement on the medicine label: - (CHILD) ‘Keep out of reach of children’ (or words to that effect).

 

3862

PIMPINELLA SAXIFRAGA

A, E, H

 

3863

PINE NEEDLE OIL SCOTCH

A, E, H

 

3864

PINE NEEDLE OIL TERPENELESS

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3865

PINE OIL AROMATIC

A, E, H

 

3866

PINE OIL PUMILIO

A, E, H

 

3867

PINEAPPLE

E

 

3868

PINEAPPLE OILS

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3869

PINELLIA TERNATA

A, H

 

3870

PINUS CONTORTA

A, E, H

 

3871

PINUS ELLIOTTII

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3872

PINUS MASSONIANA

A, E, H

When the plant preparation is oil or distillate the total concentration of Pinus massoniana oil or distillate in the preparation must be no more than 25%.

 

3873

PINUS MONTICOLA

A, E, H

 

3874

PINUS MUGO

A, E, H

 

3875

PINUS PALUSTRIS

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3876

PINUS PINASTER

A, E, H

When the plant preparation is oil or distillate the total concentration of Pinus pinaster oil or distillate in the preparation must be no more than 25%.

 

3877

PINUS PONDEROSA

A, E, H

 

3878

PINUS RADIATA

A, E, H

 

3879

PINUS STROBUS

A, E, H

 

3880

PINUS SYLVESTRIS

A, E, H

 

3881

PINUS TABULIFORMIS

A, E, H

 

3882

PINUS YUNNANENSIS

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3883

PIPENZOLATE BROMIDE

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

3884

PIPER CHABA

A, E, H

 

3885

PIPER CUBEBA

A, E, H

 

3886

PIPER KADSURA

A, E, H

 

3887

PIPER LONGUM

A, E, H

 

3888

PIPER METHYSTICUM

A, H

Kavalactones (of Piper methysticum) is a mandatory component of Piper methysticum.

Only for oral use when the dosage form is 'tablet' or 'capsule'; or when the container type is 'tea bag'.

When used in oral medicines, the maximum daily dose of kavalactones (of Piper methysticum) must be no more than 250 mg.

If the dosage form is tablet or capsule then the quantity of kavalactones (of Piper methysticum) must be no more than 125 mg per tablet or capsule.

Oral medicines containing more than 25 mg of kavalactones (of Piper methysticum) per dose require the following warning statement on the medicine label:

- (PIPER) 'Not for prolonged use. If symptoms persist - seek advice from a healthcare practitioner. Not recommended for pregnant or lactating women (or words to that effect). May harm the liver'.

The plant part must be root or rhizome.

When for oral use, the medicine may only contain dried whole or peeled root or rhizome or aqueous dispersions or aqueous extracts of whole or peeled root or rhizome.

When for topical use on the rectum, vagina or throat, the medicine may only contain dried whole or peeled root or rhizome or aqueous dispersions or aqueous extracts of whole or peeled root or rhizome.

When the container type is tea bag the maximum quantity per tea bag must be no more than 3 grams of dried whole or peeled root or rhizomes.

 

3889

PIPER NIGRUM

A, E, H

 

3890

PIPER SARMENTOSUM

A, E, H

 

3891

PIPERIDINE

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

3892

PIPERINE

E

Permitted for use only in combination with other permitted ingredients as a flavour proprietary formulation.

The total flavour proprietary formulation in a medicine must not be more than 5% and the concentration of piperine in the medicine must not be more than 0.15%.

 

 

3893

PIPERITONE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

3894

PIPERONAL

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

3895

PIPERONYL ACETONE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used as a flavour the total flavour concentration in a medicine must be no more than 5%.

If used as in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3896

PIPERONYL BUTOXIDE

E

Only for use in topical medicines for dermal application.

The medicine requires the following warning statement on the medicine label:

- (PIPBUT) 'Contains piperonyl butoxide' (or words to that effect).

 

3897

PIROCTONE OLAMINE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 1% in wash-on/wash-off medicines and 0.5% in leave-on medicines.

 

3898

PISCIDIA PISCIPULA

A, E, H

 

3899

PISTACIA LENTISCUS

A, E, H

 

3900

PISUM SATIVUM

A, E, H

 

3901

PLACENTA

H

Only for use as an active homoeopathic ingredient.

 

3902

PLANTAGO AFRA

A, E, H

When a dose for children is stated and the plant part is flower, seed or pollen, the medicine requires the following warning statement on the medicine label:

- (PSYLL) 'On medical advice' (or words to that effect).

 

3903

PLANTAGO ARENARIA

A, H

When a dose for children is stated and the plant part is flower, seed or pollen, the medicine requires the following warning statement on the medicine label:

- (PSYLL) 'On medical advice' (or words to that effect).

 

3904

PLANTAGO ASIATICA

A, H

When a dose for children is stated and the plant part is flower, seed or pollen, the medicine requires the following warning statement on the medicine label:

- (PSYLL) 'On medical advice' (or words to that effect).

 

3905

PLANTAGO LANCEOLATA

A, E, H

The medicine requires the following warning statement on the medicine label:

- (CHILD5) 'Use in children under 3 years is not recommended’

When a dose for children is stated and the plant part is flower, seed or pollen, the medicine requires the following warning statement on the medicine label:

- (PSYLL) 'On medical advice' (or words to that effect).

 

3906

PLANTAGO MAJOR

A, E, H

When a dose for children is stated and the plant part is flower, seed or pollen, the medicine requires the following warning statement on the medicine label:

- (PSYLL) 'On medical advice' (or words to that effect).

 

3907

PLANTAGO OVATA

A, H

When a dose for children is stated and the plant part is flower, seed or pollen, the medicine requires the following warning statement on the medicine label:

- (PSYLL) 'On medical advice' (or words to that effect).

 

3908

PLANTAGO SEED DRY

A, H

When a dose for children is stated, the medicine requires the following warning statement on the medicine label:

- (PSYLL) 'On medical advice' (or words to that effect).

 

3909

PLATANUS OCCIDENTALIS

A, E, H

 

3910

PLATANUS RACEMOSA

A, H

 

3911

PLATANUS X ACERIFOLIA

A, H

 

3912

PLATYCODON GRANDIFLORUS

A, E, H

 

3913

PLECTRANTHUS BARBATUS

A, E, H

 

3914

PLICATONE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3915

PLUM

E

 

3916

PLUMBAGO EUROPAEA

A, H

 

3917

PLUMERIA ALBA

A, E, H

 

3918

PLUMERIA RUBRA

A, E, H

 

3919

POA NEMORALIS

A, H

 

3920

POA PRATENSIS

A, H

 

3921

PODOPHYLLUM PELTATUM

A, H

Podophyllin and podophyllotoxin are mandatory components of Podophyllum peltatum.

The concentration of podophyllin in the medicine must be no more than 1 mg/kg or 1 mg/L or 0.0001%.

The concentration of podophyllotoxin in the medicine must be no more than 10 mg/kg or 10 mg/L or 0.001%.

 

3922

POGOSTEMON CABLIN

A, E, H

 

3923

POLACRILIN

E

 

3924

POLACRILIN POTASSIUM

E

 

3925

POLAPREZINC

A

Only for use in oral medicines.

Zinc is a mandatory component of Polaprezinc.

The maximum recommended daily dose must be no more than 34 milligrams of zinc sourced from polaprezinc.

When for internal use, the maximum recommended daily dose must be no more than 50mg of zinc.

When for internal use and the maximum recommended daily dose is more than 25mg but no more than 50mg of zinc, the medicine requires the following warning statement on the medicine label:

- (ZINC) 'WARNING: May be dangerous if taken in large amounts or for a long period.' OR 'WARNING: Contains zinc which may be dangerous if taken in large amounts or for a long period' (or words to that effect).

 

3926

POLIGLUSAM

A, E

When for internal use, the following warning statements are required on the medicine label:

- (CHITO) 'Poliglusam should be taken at least one hour after any other medication as it may reduce the effect of other medication' (or words to that effect); and

- (SFOOD) 'Derived from seafood'.

When for internal use and the dosage form is a powdered preparation, the medicine requires the following warning statements on the medicine label:

- (DNTPOW) 'Do not take powder alone. Mix with food or fluid'.

When used as an excipient, only for use in topical medicines for dermal application.

In addition, when the ingredient is included in a medicine that is listed in the Register:

- on or after 1 July 2018, the medicine must comply with all requirements under (a) & (b);

- before 1 July 2018 and supplied on or after 1 January 2020, the medicine must comply with all requirements under (a) & (b); or

- before 1 July 2018 and supplied before 1 January 2020, the medicine may comply with requirements under (a) & (b).

a) The average molecular mass of poliglusam must be greater than 2 kilodaltons.

b) When for internal use, the medicine must not contain more than 1750 milligrams of poliglusam per maximum recommended daily dose.

 

3927

POLIGLUSAM DERIVED FROM ASPERGILLUS NIGER

A, E

When for oral use, the medicine must provide no more than 2000 milligrams of Poliglusam derived from Aspergillus niger per maximum recommended daily dose and requires the following warning statement on the medicine label:

- (CHITO) 'Poliglusam should be taken at least one hour after any other medication as it may reduce the effect of other medication' (or words to that effect).

If the medicine is a powdered dosage form, the medicine also requires the following warning statement on the medicine label:

- 'Do not take powder alone. Mix with food or fluid.'

When used as an excipient, Poliglusam derived from Aspergillus niger is only permitted for use in topical medicines for dermal application.

 

3928

POLLACK-LIVER OIL

A, E

Colecalciferol and Vitamin A are mandatory components of Pollack-liver oil.

When for use in topical medicines, the concentration of Vitamin A in the medicine must be no more than 1%.

When for internal use, the maximum daily dose must be no more than 3000 micrograms of Retinol Equivalents.

When preparations for internal use in adults contain more than 33 micrograms of retinol equivalents per dosage unit in divided preparations or per gram of an undivided preparation, the medicine requires the following warning statements on the medicine label:

- (VITA2) ‘WARNING: If you are pregnant - or considering becoming pregnant - do not take vitamin A supplements without consulting your doctor or pharmacist [or words to that effect].’ NOTE: Position this warning at the beginning of the directions for use.

- (VITA4) ‘WARNING - When taken in excess of 3000 micrograms retinol equivalents - Vitamin A can cause birth defects.’ NOTE: Position this warning at the beginning of the directions for use.

- (VITA3) ‘The recommended daily amount of Vitamin A from all sources is 700 micrograms retinol equivalents for women and 900 micrograms retinol equivalents for men.’

When for internal use, the maximum recommended daily dose must be no more than 25 micrograms of Vitamin D.

 

 

3929

POLLEN

E

The medicine requires the following warning statement on the medicine label:

- (POLLEN) 'This medicine can cause severe allergic reactions' (or words to that effect).

 

3930

POLOXAMER

E

Only for use in topical medicines for dermal application.

 

3931

POLOXAMINE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3932

POLOXAMINE 1301

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

3933

POLY C10-30 ALKYL ACRYLATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 2%.

 

3934

POLYACRYLAMIDE

E

Only for use in topical medicines for dermal application.

Acrylamide is a mandatory component of Polyacrylamide.

The concentration of Acrylamide in the medicine must be no more than 0.01%.

 

3935

POLYACRYLATE CROSSPOLYMER-6

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 2%.

 

3936

POLYACRYLATE-1 CROSSPOLYMER

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 0.4%.

 

3937

POLYACRYLIC ACID

E

 

3938

POLYAMINO SUGAR CONDENSATE

E

Only for use in topical medicines for dermal application.

 

3939

POLYAMINOPROPYL BIGUANIDE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.3%.

 

3940

POLYBUTENE

E

Only for use in topical medicines for dermal application.

 

3941

POLYBUTYLENE GLYCOL/PPG-9/1 COPOLYMER

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 2%.

 

3942

POLYCAPROLACTONE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.1%.

 

3943

POLYDECENE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 6%.

 

3944

POLYDEXTROSE

E

 

3945

POLYDIETHYLSILOXANE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 5%.

 

3946

POLYDIMETHYL SILOXANE

E

Permitted for use only in combination with other permitted ingredients as a printing ink.

If used in a printing ink the total printing ink concentration in a medicine must be no more than 0.1%

 

3947

POLYESTER-10

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 1.5%.

 

3948

POLYESTER-25

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 10%.

 

3949

POLYESTER-7

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 5%.

 

3950

POLYESTER-8

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration of Polyester-8 must be no more than 5%.

 

3951

POLYETHYLENE

E

 

3952

POLYGALA CHINENSIS

A, H

 

3953

POLYGALA SENEGA

A, E, H

Except when used in a medicine containing only homoeopathic preparations, a child resistant closure and restricted flow insert must be fitted onto the container.

 

3954

POLYGALA SIBIRICA

A, E, H

Only for use when the plant part is root or root bark.

 

3955

POLYGALA TENUIFOLIA

A

Only for use when the plant part is root or root bark.

 

3956

POLYGLYCERYL-10 PENTASTEARATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 1.5%.

 

3957

POLYGLYCERYL-2 DIISOSTEARATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 3.0%.

 

3958

POLYGLYCERYL-2 DIPOLYHYDROXYSTEARATE

E

Only for use in topical medicines for dermal application. 

The concentration in the medicine must be no more than 5%.

 

3959

POLYGLYCERYL-2 TRIISOSTEARATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

When the concentration of polyglyceryl-2 triisostearate is greater than 3%, the medicine must not be intended for use on damaged skin.

The concentration in the medicine must not be more than 5%.

 

3960

POLYGLYCERYL-2-PEG-4 STEARATE

E

Only for use in topical medicines for dermal application.

 

3961

POLYGLYCERYL-3 BEESWAX

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 0.5%.

 

3962

POLYGLYCERYL-3 DIISOSTEARATE

E

Only for use in topical medicines for dermal application.

 

3963

POLYGLYCERYL-3 DISTEARATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.5%.

 

3964

POLYGLYCERYL-3 METHYLGLUCOSE DISTEARATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 6%.

 

3965

POLYGLYCERYL-3 POLYDIMETHYLSILOXYETHYL DIMETHICONE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 5.5%.

 

3966

POLYGLYCERYL-3 POLYRICINOLEATE

E

 

3967

POLYGLYCERYL-3 STEARATE/ISOSTEARATE/DIMER DILINOLEATE CROSSPOLYMER

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 5%.

 

3968

POLYGLYCERYL-4 DIISOSTEARATE/POLYHYDROXYSTEARATE/SEBACATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 3%.

 

3969

POLYGLYCERYL-4 ISOSTEARATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 5%.

 

3970

POLYGLYCERYL-4 OLEATE

E

Only for use in topical medicines for dermal application.

 

3971

POLYGLYCERYL-6 POLYRICINOLEATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 1%.

 

3972

POLYGLYCERYL-6 RICINOLEATE

E

Only for use in topical medicines for dermal application.

 

3973

POLYGONATUM MULTIFLORUM

A, H

 

3974

POLYGONATUM OFFICINALE

A, H

 

3975

POLYGONATUM SIBIRICUM

A, E, H

 

3976

POLYGONUM AVICULARE

A, E, H

When used as an excipient, the medicine is only for use in topical medicines for dermal application and not to be included in medicines intended for use on damaged skin or in the eye.

When used as an excipient, the concentration in the medicine must be no more than 0.16%.

 

3977

POLYGONUM BISTORTA

A, H

 

3978

POLYGONUM ODORATUM

A, H

 

3979

POLYHYDROXYSTEARIC ACID

E

Only for use in topical medicines for dermal application.

 

3980

POLYISOBUTYLENE

E

Only for use when the dosage form is 'chewing gum'.

Must comply with: a) the Polyisobutylene monograph in the Food Chemicals Codex published by the United States Pharmacopeial Convention, as in force or existing from time to time; and b) the requirements for residual solvents and catalysts in the British Pharmacopoeia or the United States Pharmacopeia National Formulary, as in force or existing from time to time.

 

3981

POLYISOPRENE

E

Only for use in topical medicines for dermal application.

 

3982

POLYLIMONENE

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

3983

POLYMETHACRYLIC ACID

E

 

3984

POLYMETHYL METHACRYLATE

E

Only for use in topical medicines for dermal application.

 

3985

POLYMETHYLSILSESQUIOXANE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 3%.

 

3986

POLYPORUS UMBELLATUS

A, H

 

3987

POLYPROPYLENE

E

Only for use in topical medicines for dermal application.

 

3988

POLYPROPYLENE GLYCOL

E

Permitted for use only in combination with other permitted ingredients as part of a flavour or fragrance proprietary excipient formulation.

When used in a flavour, the total flavour proprietary excipient formulation in a medicine must be no more than 5%.

When used in a fragrance, the total fragrance proprietary excipient formulation in a medicine must be no more than 1%.

 

3989

POLYQUATERNIUM-10

E

Only for use in topical medicines for dermal application.

 

3990

POLYQUATERNIUM-11

E

Only for use in topical medicines for dermal application.

 

3991

POLYQUATERNIUM-22

E

Only for use in wash-off topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 2%.

 

3992

POLYQUATERNIUM-24

E

Only for use in topical medicines for dermal application.

 

3993

POLYQUATERNIUM-28

E

Only for use in topical medicines for dermal application.

 

3994

POLYQUATERNIUM-37

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 2.5%.

 

3995

POLYQUATERNIUM-44

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.3%.

 

3996

POLYQUATERNIUM-51

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 5%.

 

3997

POLYQUATERNIUM-7

E

Only for use in topical medicines for dermal application.

 

3998

POLYSILICONE-11

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 2.1%

 

3999

POLYSILICONE-14

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration of Polysilicone-14 must be no more than 1%.

 

4000

POLYSILICONE-15

A

Only for use as an active ingredient in sunscreens for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 10%.

When used in primary sunscreen products and listed in the Register on or after 1 January 2018, the medicine must have the following statements on the medicine label:

- (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and

- (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).

When used in primary sunscreen products and listed in the Register before 1 January 2018, the medicine requires the following statements on the medicine label if supplied after 1 July 2019:

- (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and

- (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).

 

4001

POLYSILICONE-2

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.13%.

 

4002

POLYSORBATE 20

E

 

4003

POLYSORBATE 40

E

 

4004

POLYSORBATE 60

E

 

4005

POLYSORBATE 65

E

 

4006

POLYSORBATE 80

E

 

4007

POLYSORBATE 85

E

Only for use in topical medicines for dermal application.

 

4008

POLYTEF

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.5%.

 

4009

POLYURETHANE-34

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 2% in spray applications and 6% in non-spray applications.

 

4010

POLYURETHANE-62

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin. The concentration in the medicine must be no more than 5%.

 

 

4011

POLYVINYL ACETATE

E

Only for use when the dosage form is chewing gum.

 

4012

POLYVINYL ACETATE PHTHALATE

E

 

4013

POLYVINYL ALCOHOL

E

 

4014

POLYVINYL CHLORIDE

E

Only for use in topical medicines for dermal application.

 

4015

POMEGRANATE

E

 

4016

PONCEAU SX

E

Permitted for use only as a colour for topical use.

 

4017

PONCIRUS TRIFOLIATA

A, H

When used internally, oxedrine is a mandatory component of Poncirus trifoliata.

The quantity of Oxedrine in the maximum recommended daily dose must be no more than 30 mg.

 

4018

PONGAMOL

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 1%.

 

4019

POPPY SEED

E, H

 

4020

POPPY SEED OIL

E, H

 

4021

POPULUS ALBA

A, H

 

4022

POPULUS BALSAMIIFERA

A, E, H

 

4023

POPULUS CANDICANS

A, H

 

4024

POPULUS DELTOIDES

A, H

 

4025

POPULUS NIGRA

A, H

 

4026

POPULUS TREMULA

A, H

 

4027

POPULUS TREMULOIDES

A, H

 

4028

PORCINE

H

Only for use as an active homoeopathic ingredient. 

 

4029

PORPHYRIDIUM PURPUREUM EXTRACT

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.5%.

 

4030

PORTULACA OLERACEA

A, E, H

 

4031

POTABLE WATER

E

 

4032

POTASSIUM ACETATE

E

 

4033

POTASSIUM ARSENITE

H

Only for use as an active homoeopathic ingredient.

 

4034

POTASSIUM ASCORBATE

A, E, H

When for oral or sublingual use, potassium is a mandatory component of potassium ascorbate.

 

 

4035

POTASSIUM ASCORBATE DIHYDRATE

A, E, H

When for oral or sublingual use, potassium is a mandatory component of potassium ascorbate dihydrate.

 

 

4036

POTASSIUM ASCORBYL TOCOPHERYL PHOSPHATE

E

Only for use in topical medicines for dermal application.

 

4037

POTASSIUM ASPARTATE

A, E, H

When used as an active ingredient and the medicine is intended as a mineral supplementation, potassium is a mandatory component of potassium aspartate.

 

 

4038

POTASSIUM ASPARTATE DIHYDRATE

A, E, H

If used as an active ingredient and the preparation is intended as a mineral supplementation, potassium is a mandatory component of Potassium aspartate dihydrate. The percentage of potassium from potassium aspartate dihydrate should be calculated based on the molecular weight of potassium aspartate dihydrate.

 

4039

POTASSIUM ASPARTATE MONOHYDRATE

A, E

If used as an active ingredient and the preparation is intended as a mineral supplementation, potassium is a mandatory component of Potassium aspartate monohydrate. The percentage of potassium from potassium aspartate monohydrate should be calculated based on the molecular weight of potassium aspartate monohydrate.

 

4040

POTASSIUM BICARBONATE

E

 

4041

POTASSIUM BROMIDE

H

Only for use as an active homoeopathic ingredient. 

 

4042

POTASSIUM CARBONATE

E, H

When used in a solid preparation, the pH of a 10 g/L aqueous solution must not be more than 11.5.

When used in a liquid or a semi-solid preparation, the pH of the preparation must not exceed 11.5.

 

 

4043

POTASSIUM CETYL PHOSPHATE

E

Only for use in topical medicines for dermal application.

 

4044

POTASSIUM CHLORIDE

A, E, H

When for oral use:

a) potassium is a mandatory component of potassium chloride;

b) the medicine requires the following warning statement on the medicine label:

- (POTAS) 'Contains potassium. If you have kidney disease or are taking heart or blood pressure medicines - consult your doctor or pharmacist before use. Keep out of reach of children.'; and

c) other than when used for oral rehydration therapy, the concentration must be no more than 550 mg per dosage unit.

Medicines for use as oral rehydration therapy, are subject to the following conditions:

a) the medicine complies with the requirements specified in the British Pharmacopoeia, as in force or existing from time to time, for Oral Rehydration Salts;

b) the sodium, potassium and glucose content, and total osmolarity of the solution after it has been prepared according to the instructions on the packet are consistent with the criteria specified by the World Health Organisation (WHO) and the United Nations Children's Fund (UNICEF) in the document 'Expert consultation on oral rehydration salts formulation' 18 July 2001; and

c) the medicine requires the warning statements:

- (UOAD) 'Use only as directed'

- (DIAR3) 'If diarrhoea persists, seek medical advice.'

When for dental use, the concentration in the medicine must be no more than 3.75%.

 

4045

POTASSIUM CITRATE

A, E, H

When used as an active ingredient and the medicine is intended as a mineral supplementation, potassium is a mandatory component of potassium citrate.

 

 

4046

POTASSIUM COCOYL HYDROLYSED COLLAGEN

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 10%.

 

4047

POTASSIUM COCOYL HYDROLYSED SOY PROTEIN

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.15%.

 

4048

POTASSIUM DICHROMATE

H

Only for use as an active homoeopathic ingredient.

 

4049

POTASSIUM GLUCONATE

A, E, H

When used as an active ingredient and the medicine is intended as a mineral supplementation, potassium is a mandatory component of potassium gluconate.

 

 

4050

POTASSIUM GLYCEROPHOSPHATE

A, E, H

When used as an active ingredient and the medicine is intended as a mineral supplementation, potassium is a mandatory component of potassium glycerophosphate.

 

 

4051

POTASSIUM HYDROXIDE

E

The concentration in the medicine must be no more than 5%.

When used in a solid preparation, the pH of a 10 g/L aqueous solution must not be more than 11.5.

When used in a liquid or a semi-solid preparation, the pH of the preparation must not exceed 11.5.

 

4052

POTASSIUM HYDROXYCITRATE

A, H

 

4053

POTASSIUM IODATE

A, H

Iodine is a mandatory component of potassium iodate.

The percentage of iodine from potassium iodate should be calculated based on the molecular weight of potassium iodate.

When for use in adults, the medicine must contain a daily dose of no more than 505 micrograms of potassium iodate.

When for use in children aged 1-3 years, the medicine must contain a daily dose of no more than 337 micrograms of potassium iodate.

 

4054

POTASSIUM IODIDE

A, E, H

Iodine is a mandatory component of potassium iodide.

The percentage of iodine from potassium iodide should be calculated based on the molecular weight of potassium iodide.

When for internal use, the maximum recommended daily dose of the medicine must contains less than 300 micrograms of iodine.

When for external use, the concentration of iodine in the medicine (excluding salts derivatives or iodophors) must not exceed 2.5%.

 

 

4055

POTASSIUM METABISULFITE

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4056

POTASSIUM METAPHOSPHATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.5%.

 

4057

POTASSIUM NITRATE

A, H

Only for dental use.

The concentration in the medicine must be no more than 5%.

 

4058

POTASSIUM OROTATE

A, E, H

When used as an active ingredient and the medicine is intended as a mineral supplementation, potassium is a mandatory component of potassium orotate.

When used in a solid preparation, the pH of a 10 g/L aqueous solution must not be more than 11.5.

When used in a liquid or a semi-solid preparation, the pH of the preparation must not exceed 11.5.

 

 

4059

POTASSIUM PYROPHOSPHATE

E

Only for oral application, dental or topical use.

Not to be included in topical medicines intended for use in the eye.

The concentration in the medicine must be no more than 3%.

 

4060

POTASSIUM SORBATE

E

The medicine requires the following warning statement on the medicine label:

- (SORB8) 'Contains sorbates' (or word to this effect) if medicine contains two or more sorbate sources OR 'Contains [insert the approved name of sorbate source used]' (or words to this effect) if medicine contains one sorbate source.

 

4061

POTASSIUM STANNATE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4062

POTASSIUM STEARATE

E

Only for use in topical medicines for dermal application.

 

4063

POTASSIUM SULFATE

A, E, H

When used as an active ingredient and the medicine is intended as a mineral supplementation, potassium is a mandatory component of potassium sulfate.

When used in a solid preparation, the pH of a 10 g/L aqueous solution must not be more than 11.5.

When used in a liquid or a semi-solid preparation, the pH of the preparation must not exceed 11.5.

 

4064

POTATO STARCH

E

 

4065

POTENTILLA ANSERINA

A, H

 

4066

POTENTILLA CHINENSIS

A, H

 

4067

POTENTILLA DISCOLOR

A, H

 

4068

POTENTILLA ERECTA

A, E, H

 

4069

POTENTILLA REPTANS

A, H

 

4070

POTERIUM OFFICINALE

A, E, H

 

4071

POTERIUM SANGUISORBA

A, H

 

4072

POVIDONE

E

 

4073

POWDERED CELLULOSE

E

 

4074

PPG-1-PEG-9 LAURYL GLYCOL ETHER

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 5%.

 

4075

PPG-12/SMDI COPOLYMER

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 2%.

 

4076

PPG-15 STEARYL ETHER

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 4%.

 

 

4077

PPG-15 STEARYL ETHER BENZOATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 1.4%.

 

4078

PPG-17/IPDI/DMPA COPOLYMER

E

Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye or on damaged skin.

The concentration of PPG-17/IPDI/DMPA Copolymer in the medicine must be no more than 10%.

 

4079

PPG-2 LANOLIN ALCOHOL ETHER

E

Only for use in topical medicines for dermal application.

 

4080

PPG-2 MYRISTYL ETHER PROPIONATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 5%.

 

4081

PPG-20 LANOLIN ALCOHOL ETHER

E

Only for use in topical medicines for dermal application.

 

4082

PPG-20 METHYL GLUCOSE ETHER

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.5%.

 

4083

PPG-20 METHYL GLUCOSE ETHER DISTEARATE

E

Only for use in topical medicines for dermal application.

 

4084

PPG-3 HYDROGENATED CASTOR OIL

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. 

The concentration in the medicine must be no more than 6%.

 

4085

PPG-3 MYRISTYL ETHER

E

Only for use in topical medicines for dermal application.

 

4086

PPG-5-CETETH-20

E

Only for use in topical medicines for dermal application.

 

4087

PPG-5-LAUROMACROGOL 250

E

Only for use in topical medicines for dermal application.

 

4088

PRALINE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4089

PREGELATINISED MAIZE STARCH

E

 

4090

PREGELATINISED POTATO STARCH

E

 

4091

PREGELATINISED RICE STARCH

E

 

4092

PREGELATINISED WHEAT STARCH

E

When the route of administration is other than topical or mucosal, gluten is a mandatory component of pregelatinised wheat starch.

When the route of administration is other than topical or mucosal, the medicine requires the following warning statement on the medicine label:

- (GLUTEN) 'Contains [insert name of ingredient]' (or words to that effect).

 

4093

PRENYL ACETATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4094

PRICKLY ASH BARK DRY

A, H

 

4095

PRICKLY ASH BARK POWDER

A, H

 

4096

PRIMULA VERIS

A, E, H

 

4097

PRIMULA VULGARIS

A, E, H

 

4098

PRINSEPIA UNIFLORA

A, H

 

4099

PROBOSCIDEA PARVIFLORA

A, H

 

4100

PROGESTERONE

H

Only for use as an active homoeopathic ingredient. 

 

4101

PROLINE

A, E

 

4102

PROPAN-1-OL

E

Only for use in topical medicines for dermal application.

The concentration in the medicine must be no more than 18%.

 

4103

PROPANE

E

Only for use as an excipient propellant ingredient.

 

4104

PROPANEDIOL

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 10%.

 

4105

PROPENYL GUAETHOL

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4106

PROPIONALDEHYDE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4107

PROPIONIC ACID

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4108

PROPIONYLLEVOCARNITINE HYDROCHLORIDE

A, H

 

4109

PROPOLIS

A, E

Lead is a mandatory component of Propolis.

The concentration of lead in the medicine must be no more than 0.001%.

When used topically, the medicine requires the following warning statement on the medicine label:

-(PROP1) 'WARNING: Propolis may cause skin irritation. Test before use'

When used for other than for topical, the medicine requires the following warning statement on the medicine label:

- (PROP2) 'Warning: Propolis may cause allergic reactions. If irritation or swelling of the mouth or throat occurs, discontinue use.'

 

4110

PROPOLIS BALSAM

A, E

Lead is a mandatory component of Propolis balsam.

The concentration of lead in the medicine must be no more than 0.001%.

When used topically, the medicine requires the following warning statement on the medicine label:

-(PROP1) 'WARNING: Propolis may cause skin irritation. Test before use'

When used for other than for topical, the medicine requires the following warning statement on the medicine label:

- (PROP2) 'Warning: Propolis may cause allergic reactions. If irritation or swelling of the mouth or throat occurs, discontinue use.'

 

4111

PROPOLIS DRY EXTRACT

A, E

Lead is a mandatory component of Propolis dry extract.

The concentration of lead in the medicine must be no more than 0.001%.

When used topically, the medicine requires the following warning statement on the medicine label:

-(PROP1) 'WARNING: Propolis may cause skin irritation. Test before use'

When used for other than for topical, the medicine requires the following warning statement on the medicine label:

- (PROP2) 'Warning: Propolis may cause allergic reactions. If irritation or swelling of the mouth or throat occurs, discontinue use.'

 

4112

PROPOLIS LIQUID EXTRACT

A, E

Lead is a mandatory component of Propolis liquid extract.

The concentration of lead in the medicine must be no more than 0.001%.

When used topically, the medicine requires the following warning statement on the medicine label:

-(PROP1) 'WARNING: Propolis may cause skin irritation. Test before use'

When used for other than for topical, the medicine requires the following warning statement on the medicine label:

- (PROP2) 'Warning: Propolis may cause allergic reactions. If irritation or swelling of the mouth or throat occurs, discontinue use.'

 

4113

PROPOLIS RESIN

A, E

Lead is a mandatory component of propolis resin.

The concentration of lead in the medicine must be no more than 0.001%.

When used topically, the medicine requires the following warning statement on the medicine label:

-(PROP1) 'WARNING: Propolis may cause skin irritation. Test before use'

When used for other than for topical, the medicine requires the following warning statement on the medicine label:

- (PROP2) 'Warning: Propolis may cause allergic reactions. If irritation or swelling of the mouth or throat occurs, discontinue use.'

 

4114

PROPOLIS TINCTURE

A, E

Lead is a mandatory component of Propolis tincture.

The concentration of lead in the medicine must be no more than 0.001%.

When used topically, the medicine requires the following warning statement on the medicine label:

-(PROP1) 'WARNING: Propolis may cause skin irritation. Test before use'

When used for other than for topical, the medicine requires the following warning statement on the medicine label:

- (PROP2) 'Warning: Propolis may cause allergic reactions. If irritation or swelling of the mouth or throat occurs, discontinue use.'

 

4115

PROPYL ACETATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4116

PROPYL CAPROATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4117

PROPYL GALLATE

E

 

4118

PROPYL HYDROXYBENZOATE

E

Medicines containing hydroxybenzoates require the following warning statement on the medicine label:

- (TOTBNZ) ‘Contains hydroxybenzoates’ (or words to this effect) if the medicine contains more than one hydroxybenzoate source OR ‘Contains [insert the approved name of hydroxybenzoate used]’ (or words to this effect) if product contains one hydroxybenzoate source.

 

4119

PROPYLENE CARBONATE

E

Only for use in topical medicines for dermal application.

 

4120

PROPYLENE GLYCOL

E

 

4121

PROPYLENE GLYCOL ALGINATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4122

PROPYLENE GLYCOL DIBENZOATE

E

Only for use in topical medicines for dermal application only and not to be used in topical medicines intended for use in the eye.

The concentration in the medicine must be no more than 20%.

 

4123

PROPYLENE GLYCOL DIDECANOATE

E

Only for use in topical medicines for dermal application only and not to be used in topical medicines intended for use in the eye.

The concentration in the medicine must be no more than 1%.

 

4124

PROPYLENE GLYCOL DIOCTANOATE

E

Only for use in topical medicines for dermal application.

 

4125

PROPYLENE GLYCOL DIOCTANOATE/DIDECANOATE

E

Only for use in topical medicines for dermal application.

 

4126

PROPYLENE GLYCOL DIPELARGONATE

E

Only for use in topical medicines for dermal application.

 

4127

PROPYLENE GLYCOL ISOCETETH-3 ACETATE

E

Only for use in topical medicines for dermal application only and not to be used in topical medicines intended for use in the eye.

The concentration in the medicine must be no more than 1%.

 

4128

PROPYLENE GLYCOL ISOSTEARATE

E

Only for use in topical medicines for dermal application.

 

4129

PROPYLENE GLYCOL MONOLAURATE

E

Only for use in topical medicines for dermal application.

 

4130

PROPYLENE GLYCOL MONOSTEARATE

E

Only for use in topical medicines for dermal application.

 

4131

PROPYLENE GLYCOL MYRISTYL ETHER ACETATE

E

Only for use in topical medicines for dermal application.

 

4132

PROSOPIS JULIFLORA

A, H

 

4133

PROTEASE

A

Must be derived from Aspergillus oryzae or Aspergillus niger.

When the dosage form is undivided, the units 'haemoglobin unit on the tyrosine basis per gram' and 'Thousand haemoglobin units on the tyrosine basis per gram' are permitted.

When the dosage form is divided, the units 'haemoglobin units on the tyrosine basis' and 'thousand haemoglobin units on the tyrosine basis' are permitted.

 

4134

PROTEIN HYDROLYSATE

E

 

4135

PRUNE JUICE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4136

PRUNE JUICE CONCENTRATE

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4137

PRUNELLA VULGARIS

A, H

 

4138

PRUNUS AFRICANA

A, E, H

Amygdalin and hydrocyanic acid are mandatory components of Prunus africana.

The concentration of Amygdalin in the medicine must be 0%.

The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.

 

4139

PRUNUS ARMENIACA

A, E, H

Amygdalin and hydrocyanic acid are mandatory components of Prunus armeniaca and must be declared in the application.

The concentration of Amygdalin in the medicine must be 0%.

The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.

 

4140

PRUNUS AVIUM

A, E, H

Amygdalin and hydrocyanic acid are mandatory components of Prunus avium.

The concentration of Amygdalin in the medicine must be 0%.

The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.

 

4141

PRUNUS CERASIFERA

A, E, H

Amygdalin and hydrocyanic acid are mandatory components of Prunus cerasifera.

The concentration of Amygdalin in the medicine must be 0%.

The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.

 

4142

PRUNUS CERASUS

A, E, H

Amygdalin and hydrocyanic acid are mandatory components of Prunus cerasus.

The concentration of Amygdalin in the medicine must be 0%.

The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.

 

4143

PRUNUS DOMESTICA

A, E, H

Amygdalin and hydrocyanic acid are mandatory components of Prunus domestica.

The concentration of Amygdalin in the medicine must be 0%.

The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.

 

4144

PRUNUS DULCIS

A, E, H

Amygdalin and hydrocyanic acid are mandatory components of Prunus dulcis when the plant part is seed.

When the plant part is seed, the maximum recommended daily dose must be no more than the equivalent of 1mg of the dry seed.

The concentration of Amygdalin in the medicine must be 0%.

The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.

 

4145

PRUNUS HUMILIS

A, E, H

Amygdalin and hydrocyanic acid are mandatory components of Prunus humilis.

The concentration of Amygdalin in the medicine must be 0%.

The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.

 

4146

PRUNUS JAPONICA

A, E, H

Amygdalin and hydrocyanic acid are mandatory components of Prunus japonica.

The concentration of Amygdalin in the medicine must be 0%.

The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.

 

4147

PRUNUS LAUROCERASUS

A, E, H

Amygdalin and hydrocyanic acid are mandatory components of Prunus laurocerasus.

The concentration of Amygdalin in the medicine must be 0%.

The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.

 

4148

PRUNUS MUME

A, E, H

Amygdalin and hydrocyanic acid are mandatory components of Prunus mume.

The concentration of Amygdalin in the medicine must be 0%.

The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.

 

4149

PRUNUS PERSICA

A, E, H

Amygdalin and hydrocyanic acid are mandatory components of Prunus persica.

The concentration of Amygdalin in the medicine must be 0%.

The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.

 

4150

PRUNUS SALICINA

A, E, H

Amygdalin and hydrocyanic acid are mandatory components of Prunus salicina.

The concentration of Amygdalin in the medicine must be 0%.

The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.

 

4151

PRUNUS SEROTINA

A, E, H

Amygdalin and hydrocyanic acid are mandatory components of Prunus serotina.

The concentration of Amygdalin in the medicine must be 0%.

The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.

 

4152

PRUNUS SPINOSA

A, E, H

Amygdalin and hydrocyanic acid are mandatory components of Prunus spinosa.

The concentration of Amygdalin in the medicine must be 0%.

The concentration of Hydrocyanic acid in the medicine must be no more than 1 microgram/kg or 1 microgram/L or 0.0000001%.

 

4153

PRUSSIAN BLUE

E

Permitted for use only as a colour for topical use.

 

4154

PSEUDOCYDONIA SINENSIS

A, H

 

4155

PSEUDOSTELLARIA HETEROPHYLLA

A, E, H

 

4156

PSEUDOTSUGA MENZIESII

A, H

 

4157

PSEUDOWINTERA COLORATA

A, H

Only for use when the plant part is leaf.

 

4158

PSIDIUM GUAJAVA

A, E, H

 

4159

PSORALEN (OF CULLEN CORYLIFOLIUM)

E

 

4160

PSORINUM

H

Only for use as an active homoeopathic ingredient. 

 

4161

PSYLLIUM HUSK DRY

A, H

When a dose for children is stated, the medicine requires the following warning statement on the medicine label:

- (PSYLL) 'On medical advice' (or words to that effect).

 

4162

PSYLLIUM HUSK POWDER

A, E, H

When a dose for children is stated, the medicine requires the following warning statement on the medicine label:

- (PSYLL) 'On medical advice' (or words to that effect).

 

4163

PSYLLIUM SEED DRY

A, E, H

When a dose for children is stated, the medicine requires the following warning statement on the medicine label:

- (PSYLL) 'On medical advice' (or words to that effect).

 

4164

PTELEA TRIFOLIATA

A, H

 

4165

PTEROCARPUS MARSUPIUM

A, H

 

4166

PTEROCARPUS SANTALINUS

A, E, H

 

4167

PUERARIA LOBATA

A, E, H

 

4168

PUERARIA MONTANA VAR. LOBATA

A, E, H

 

4169

PULLULAN

E

 

4170

PUMICE

E

 

4171

PUMPKIN

E

 

4172

PUMPKIN SEED

E, H

 

4173

PUMPKIN SEED OIL

E, H

 

4174

PUNICA GRANATUM

A, E, H

 

4175

PURE BEE VENOM

H

Only for use as an active homoeopathic ingredient.

 

4176

PURIFIED HONEY

A, E

When the route of administration is oral, the medicine requires the following warning statement on the medicine label:

- (BABY2) 'Not suitable for infants under the age of twelve months' (or words to that effect).

When the medicine is for oral ingestion and the total amount of all sugars (monosaccharides and disaccharides such as glucose, honey, invert sugar, lactose, maltose, and sucrose) is more than 100mg in the maximum daily dose, then the medicine requires the following warning statement on the medicine label:

- (SUGARS) ‘Contains [insert name of sugar]’ if medicine contains one sugar OR ‘Contains sugars' (or words to that effect) if medicine contains two or more sugars.

If one of the sugars is lactose then the medicine also requires the following warning statement on the medicine label:

- (LACT) ‘Contains lactose' (or words to that effect).

 

4177

PURIFIED SILICEOUS EARTH

E, H

 

4178

PURIFIED TALC

E

 

4179

PURIFIED WATER

E

 

4180

PVM/MA COPOLYMER

E

 

4181

PVM/MA DECADIENE CROSSPOLYMER

E

Only for use in topical medicines for dermal application.

 

4182

PVP/EICOSENE COPOLYMER

E

Only for use in topical medicines for dermal application.

 

4183

PVP/HEXADECENE COPOLYMER

E

Only for use in topical medicines for dermal application.

 

4184

PYRETHRINS

E

Only for use in topical medicines for dermal application.

The concentration in the medicine must be no more than 10%.

The medicine requires the following warning statement on the medicine label:

- (PYRTH3) 'Contains pyrethrins [insert quantity]' (or words to that effect).

 

4185

PYRIDOXAL 5-PHOSPHATE

A, E

Pyridoxine is a mandatory component of Pyridoxal 5-phosphate.

The percentage of pyridoxine from pyridoxal 5-phosphate should be calculated based on the molecular weight of pyridoxal 5-phosphate.

The maximum recommended daily dose must provide no more than 200 mg of pyridoxine.

If the medicine contains more than 50 mg and no more than 200 mg of pyridoxine per maximum recommended daily dose the medicine requires the following warning statement on the medicine label:

- (VITB6SX) 'WARNING - Stop taking this medication if you experience tingling, burning or numbness and see your healthcare practitioner as soon as possible. [Contains vitamin B6].'

 

4186

PYRIDOXAL 5-PHOSPHATE MONOHYDRATE

A

Pyridoxine is a mandatory component of Pyridoxal 5-phosphate monohydrate.

The percentage of pyridoxine from pyridoxal 5-phosphate monohydrate should be calculated based on the molecular weight of pyridoxal 5-phosphate monohydrate.

The maximum recommended daily dose must provide no more than 200 mg of pyridoxine.

If the medicine contains more than 50 mg and no more than 200 mg of pyridoxine per maximum recommended daily dose the medicine requires the following warning statement on the medicine label:

- (VITB6SX) 'WARNING - Stop taking this medication if you experience tingling, burning or numbness and see your healthcare practitioner as soon as possible. [Contains vitamin B6].'

 

4187

PYRIDOXINE HYDROCHLORIDE

A, E, H

When not used as an active homoeopathic ingredient, pyridoxine is a mandatory component of Pyridoxine hydrochloride.

The percentage of pyridoxine from pyridoxine hydrochloride should be calculated based on the molecular weight of pyridoxine hydrochloride.

The maximum recommended daily dose must provide no more than 200 mg of pyridoxine.

If the medicine contains more than 50 mg and no more than 200 mg of pyridoxine per maximum recommended daily dose the medicine requires the following warning statement on the medicine label:

- (VITB6SX) 'WARNING - Stop taking this medication if you experience tingling, burning or numbness and see your healthcare practitioner as soon as possible. [Contains vitamin B6].'

 

4188

PYROGLUTAMIC ACID

E

 

4189

PYROLA DECORATA

A, H

 

4190

PYROLIGNEOUS ACID

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4191

PYRROSIA LINGUA

A, H

 

4192

PYRROSIA PETIOLOSA

A, H

 

4193

PYRROSIA SHEARERI

A, H

 

4194

PYRUS COMMUNIS

A, E, H

Arbutin is a mandatory component of Pyrus communis.

The concentration of arbutin in the medicine must be no more than 25 mg/Kg or 25mg /L or 0.0025 % unless used on the hair.

When for use on hair, the concentration of arbutin in the medicine must be no more than 0.74 %.

 

4195

PYRUS PYRIFOLIA

A, H

Arbutin is a mandatory component of Pyrus pyrifolia.

The concentration of arbutin in the medicine must be no more than 25 mg/Kg or 25mg /L or 0.0025 % unless used on the hair.

When for use on hair, the concentration of arbutin in the medicine must be no more than 0.74 %.

 

 

4196

PYRUVIC ACID

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4197

QUASSIA

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4198

QUASSIA AMARA

A, E, H

 

4199

QUASSIA WOOD JAMAICAN DRY

A, H

 

4200

QUASSIA WOOD JAMAICAN POWDER

A, H

 

4201

QUATERNIUM-15

E

Only for use in topical medicines for dermal application.

 

4202

QUATERNIUM-18 BENTONITE

E

Only for use in topical medicines for dermal application.

 

4203

QUATERNIUM-18 HECTORITE

E

Only for use in topical medicines for dermal application.

 

4204

QUATERNIUM-52

E

Only for use in wash-on/wash-off topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 1%.

Not be used in medicines in which N-nitroso compounds may be formed.

 

4205

QUATERNIUM-80

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 2.5%.

 

4206

QUERCETIN

A

 

4207

QUERCETIN DIHYDRATE

A

 

4208

QUERCUS ACUTISSIMA

A, H

 

4209

QUERCUS ALBA

A, E, H

 

4210

QUERCUS PALUSTRIS

A, H

 

4211

QUERCUS ROBUR

A, H

 

4212

QUERCUS RUBRA

A, H

 

4213

QUERCUS VIRGINIANA

A, H

 

4214

QUILLAIA DRY

A, H

 

4215

QUILLAIA POWDER

A, E, H

 

4216

QUILLAJA SAPONARIA

A, H

 

4217

QUINCE

E

 

4218

QUININE ARSENITE

H

Only for use as an active homoeopathic ingredient.

Quinine is a mandatory component of Quinine arsenite.

The maximum recommended daily dose must be no more than 50 mg of quinine.

 

4219

QUININE SULFATE DIHYDRATE

H

Only for use as an active homoeopathic ingredient. 

Quinine is a mandatory component of quinine sulfate dihydrate. 

The maximum recommended daily dose must be no more than 50 mg of quinine.

 

4220

QUINOLINE YELLOW

E

Permitted for use only as a colour for oral and topical use.

 

4221

QUINOLINE YELLOW ALUMINIUM LAKE

E

Permitted for use only as a colour for oral and topical use.

 

4222

QUISQUALIS INDICA

A, H

 

4223

R-ALPHA LIPOIC ACID

A

 

4224

RACEMENTHOL

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4225

RACEMIC CAMPHOR

E, H

Only for use as an active homoeopathic or excipient ingredient.

In solid and semi solid preparations, the concentration of camphor must be no more than 12.5%.

In liquid preparations other than essential oils, the concentration of camphor must be no more than 2.5%.

In essential oil preparations, if the concentration of camphor is more than 2.5% but less than or equal to 10%, and the nominal capacity of the container is less than 25 millilitres, the medicine must have a restricted flow insert fitted on the container and include the following warning statements on the medicine label:

- (CHILD) 'Keep out of reach of children' (or words to that effect); and

- (NTAKEN) 'Not to be taken'.

In essential oil preparations, if the concentration of camphor is more than 10%, and the nominal capacity of the container is less than 15 millilitres, the medicine must have a restricted flow insert fitted on the container and include the following warning statements on the medicine label:

- (CHILD) 'Keep out of reach of children' (or words to that effect); and

- (NTAKEN) 'Not to be taken'.

In essential oil preparations, if the concentration of camphor is more than 10%, and the nominal capacity of the container is more than 15 millilitres but less than or equal to 25 millilitres, the medicine must have a restricted flow insert and child resistant closure fitted on the container and include the following warning statements on the medicine label:

- (CHILD) 'Keep out of reach of children' (or words to that effect); and

- (NTAKEN) 'Not to be taken'.

If the concentration of camphor is more than 2.5%, the nominal capacity of the container must be no more than 25 millilitres.

 

4226

RADISH

E

 

4227

RAISIN JUICE CONCENTRATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4228

RANUNCULUS BULBOSUS

A, H

 

4229

RANUNCULUS FICARIA

A, H

 

4230

RANUNCULUS TERNATUS

A, H

 

4231

RAPE OIL/TUNG OIL COPOLYMER

E

Only for use in topical medicines for dermal application and not for use in topical medicines intended for use in the eye.

The concentration in the medicine must be no more than 1%.

 

4232

RAPE SEED OIL

A, E, H

Allyl isothiocyanate is a mandatory component of rape seed oil when the plant part is seed.

The concentration of allyl isothiocyanate from all ingredients in the product must be no more than 10 mg/kg or 10 mg/L or 0.001%.

 

4233

RAPHANUS SATIVUS

A, H

 

4234

RASPBERRY

E

 

4235

RASPBERRY BRANDY

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4236

RASPBERRY DISTILLATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4237

RASPBERRY ESSENCE

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4238

RASPBERRY JUICE CONCENTRATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4239

RAUWOLFIA SERPENTINA

A, H

The concentration of equivalent dry Rauwolfia serpentina in the medicine must be no more than 10mg/Kg or 10mg/L or 0.001%.

 

4240

RAUWOLFIA SERPENTINA DRY

A, H

The concentration of Rauwolfia Serpentina Dry in the medicine must be no more than 10mg/Kg or 10mg/L or 0.001%.

 

4241

RAUWOLFIA SERPENTINA POWDER

A, H

The concentration of Rauwolfia Serpentina Powder in the medicine must be no more than 10mg/Kg or 10mg/L or 0.001%.

 

4242

RED 27

E

Permitted for use only as a colour for oral and topical use.

The concentration in the medicine must be no more than 0.5%.

 

4243

RED 27 ALUMINIUM LAKE

E

Permitted for use only as a colour for oral and topical use.

The concentration in the medicine must be no more than 0.5%.

 

4244

RED ANT

H

Only for use as an active homoeopathic ingredient.

 

4245

RED CLOVER FLOWER DRY

A, H

 

4246

RED CLOVER FLOWER POWDER

A, H

 

4247

RED CORAL

H

Only for use as an active homoeopathic ingredient.

 

4248

RED DEER

A

 

4249

RED MERCURIC IODIDE

H

Only for use as an active homoeopathic ingredient.

 

4250

RED MERCURIC OXIDE

H

Only for use as an active homoeopathic ingredient.

 

4251

RED MERCURIC SULFIDE

H

Only for use as an active homoeopathic ingredient.

 

4252

REHMANNIA GLUTINOSA

A, E, H

 

4253

REL-1-((1R,2S)-1,2,3,4,5,6,7,8-OCTAHYDRO-1,2,8,8-TETRAMETHYL-2-NAPHTHALENYL)-1-ETHANONE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4254

RESORCINOL

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4255

RESORCINOL DIMETHYLETHER

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4256

RETINOL

A, E

Vitamin A is a mandatory component of retinol.

When for use in topical medicines, the concentration of Vitamin A in the medicine must be no more than 1%.

When for internal use, the maximum daily dose must be no more than 3000 micrograms of Retinol Equivalents.

When preparations for internal use in adults contain more than 33 micrograms of retinol equivalents per dosage unit in divided preparations or per gram of an undivided preparation, the medicine requires the following warning statements on the medicine label:

- (VITA2) ‘WARNING: If you are pregnant - or considering becoming pregnant - do not take Vitamin A supplements without consulting your doctor or pharmacist [or words to that effect].’ NOTE: Position this warning at the beginning of the directions for use.

- (VITA4) ‘WARNING - When taken in excess of 3000 micrograms retinol equivalents - Vitamin A can cause birth defects.’ NOTE: Position this warning at the beginning of the directions for use.

- (VITA3) ‘The recommended daily amount of Vitamin A from all sources is 700 micrograms retinol equivalents for women and 900 micrograms retinol equivalents for men.’

 

4257

RETINOL ACETATE

A, E

Vitamin A is a mandatory component of retinol acetate.

When for use in topical medicines, the concentration of Vitamin A in the medicine must be no more than 1%.

When for internal use, the maximum daily dose must be no more than 3000 micrograms of Retinol Equivalents.

When preparations for internal use in adults contain more than 33 micrograms of retinol equivalents per dosage unit in divided preparations or per gram of an undivided preparation, the medicine requires the following warning statements on the medicine label:

- (VITA2) ‘WARNING: If you are pregnant - or considering becoming pregnant - do not take Vitamin A supplements without consulting your doctor or pharmacist [or words to that effect].’ NOTE: Position this warning at the beginning of the directions for use.

- (VITA4) ‘WARNING - When taken in excess of 3000 micrograms retinol equivalents - Vitamin A can cause birth defects.’ NOTE: Position this warning at the beginning of the directions for use.

- (VITA3) ‘The recommended daily amount of Vitamin A from all sources is 700 micrograms retinol equivalents for women and 900 micrograms retinol equivalents for men.’

 

4258

RETINOL PALMITATE

A, E

Vitamin A is a mandatory component of retinol palmitate.

When for use in topical medicines, the concentration of Vitamin A in the medicine must be no more than 1%.

When for internal use, the maximum daily dose must be no more than 3000 micrograms of Retinol Equivalents.

When preparations for internal use in adults contain more than 33 micrograms of retinol equivalents per dosage unit in divided preparations or per gram of an undivided preparation, the medicine requires the following warning statements on the medicine label:

- (VITA2) ‘WARNING: If you are pregnant - or considering becoming pregnant - do not take Vitamin A supplements without consulting your doctor or pharmacist [or words to that effect].’ NOTE: Position this warning at the beginning of the directions for use.

- (VITA4) ‘WARNING - When taken in excess of 3000 micrograms retinol equivalents - Vitamin A can cause birth defects.’ NOTE: Position this warning at the beginning of the directions for use.

- (VITA3) ‘The recommended daily amount of Vitamin A from all sources is 700 micrograms retinol equivalents for women and 900 micrograms retinol equivalents for men.’

 

4259

REYNOUTRIA JAPONICA

A, E, H

When used as an excipient, only for use in topical medicines for dermal application.

 

4260

RHAMNOSE

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4261

RHAMNUS CATHARTICA

A, H

When the route of administration is oral, Hydroxyanthracene derivatives is a mandatory component of Rhamnus cathartica.

When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX2) 'Prolonged use may cause serious bowel problems'; and

- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).

When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:

- (LAX1) 'Drink plenty of water' (or words to that effect).

When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and

- (LAX4) 'This product may have laxative effect'.

When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX1) 'Drink plenty of water' (or words to that effect); and

- (LAX2) 'Prolonged use may cause serious bowel problems'.

 

4262

RHAMNUS FRANGULA

A, H

Glucofrangulins calculated as glucofrangulin A is a mandatory component of Rhamnus frangula.

When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX2) 'Prolonged use may cause serious bowel problems'; and

- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).

When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:

- (LAX1) 'Drink plenty of water' (or words to that effect).

When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and

- (LAX4) 'This product may have laxative effect'.

When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX1) 'Drink plenty of water' (or words to that effect); and

- (LAX2) 'Prolonged use may cause serious bowel problems'.

 

4263

RHATANY ROOT DRY

A, H

 

4264

RHATANY ROOT POWDER

A, H

 

4265

RHEUM OFFICINALE

A, E, H

The plant part must not be leaf.

When the route of administration is oral, Hydroxyanthracene derivatives calculated as rhein is a mandatory component of Rheum officinale.

When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX2) 'Prolonged use may cause serious bowel problems'; and

- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).

When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:

- (LAX1) 'Drink plenty of water' (or words to that effect).

When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and

- (LAX4) 'This product may have laxative effect'.

When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX1) 'Drink plenty of water' (or words to that effect); and

- (LAX2) 'Prolonged use may cause serious bowel problems'.

 

4266

RHEUM PALMATUM

A, E, H

The plant part must not be leaf.

When the route of administration is oral, Hydroxyanthracene derivatives calculated as rhein is a mandatory component of Rheum palmatum.

When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:

- (CHILD3) ‘Use in children under 12 years is not recommended’;

- (LAX2) ‘Prolonged use may cause serious bowel problems’; and

- (LAX3) ‘Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).

When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:

- (LAX1) ‘Drink plenty of water' (or words to that effect).

When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (LAX5) ‘This product contains [name of the herb(s) or the chemical component(s)]’; and

- (LAX4) ‘This product may have laxative effect’.

When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (CHILD3) ‘Use in children under 12 years is not recommended’;

- (LAX1) ‘Drink plenty of water' (or words to that effect); and

- (LAX2) ‘Prolonged use may cause serious bowel problems’.

 

4267

RHEUM RHAPONTICUM

A, E, H

The plant part must not be leaf.

When the route of administration is oral, Hydroxyanthracene derivatives is a mandatory component of Rheum rhaponticum.

When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX2) 'Prolonged use may cause serious bowel problems'; and

- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).

When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:

- (LAX1) 'Drink plenty of water' (or words to that effect).

When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and

- (LAX4) 'This product may have laxative effect'.

When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX1) 'Drink plenty of water' (or words to that effect); and

- (LAX2) 'Prolonged use may cause serious bowel problems'.

 

4268

RHEUM TANGUTICUM

A, H

The plant part must not be leaf.

When the route of administration is oral, Hydroxyanthracene derivatives calculated as rhein is a mandatory component of Rheum tanguticum.

When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX2) 'Prolonged use may cause serious bowel problems'; and

- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).

When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:

- (LAX1) 'Drink plenty of water' (or words to that effect).

When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and

- (LAX4) 'This product may have laxative effect'.

When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX1) 'Drink plenty of water' (or words to that effect); and

- (LAX2) 'Prolonged use may cause serious bowel problems'.

 

4269

RHODAMINE B

E

Permitted for use only as a colour for topical use.

 

4270

RHODINOL

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4271

RHODINYL ACETATE

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used as a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4272

RHODIOLA ROSEA

A

Only for use in oral medicines.

Only available for use when the plant preparation is dry root powder, dry root powder as an aqueous extract or dry root powder as a hydroethanolic extract with no more than 70% ethanol v/v.

 

4273

RHODODENDRON AUREUM

A, H

 

4274

RHODODENDRON FERRUGINEUM

A, H

Arbutin is a mandatory component of Rhododendron ferrugineum.

The concentration of arbutin in the medicine must be no more than 25 mg/Kg or 25mg /L or 0.0025 % unless used on the hair.

When for use on hair, the concentration of arbutin in the medicine must be no more than 0.74 %.

 

4275

RHODODENDRON MOLLE

A, H

The maximum recommended daily dose of the medicine must be no more than 1mg of the dry herbal material.

 

4276

RHUBARB

E, H

When the route of administration is oral, Hydroxyanthracene derivatives is a mandatory component of Rhubarb.

When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX2) 'Prolonged use may cause serious bowel problems'; and

- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).

When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:

- (LAX1) 'Drink plenty of water' (or words to that effect).

When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and

- (LAX4) 'This product may have laxative effect'.

When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX1) 'Drink plenty of water' (or words to that effect); and

- (LAX2) 'Prolonged use may cause serious bowel problems'.

 

4277

RHUBARB ROOT DRY

A, H

When the route of administration is oral, Hydroxyanthracene derivatives calculated as rhein is a mandatory component of rhubarb root dry.

When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX2) 'Prolonged use may cause serious bowel problems'; and

- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).

When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:

- (LAX1) 'Drink plenty of water' (or words to that effect).

When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and

- (LAX4) 'This product may have laxative effect'.

When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX1) 'Drink plenty of water' (or words to that effect); and

- (LAX2) 'Prolonged use may cause serious bowel problems'.

 

4278

RHUBARB ROOT POWDER

A, H

When the route of administration is oral, Hydroxyanthracene derivatives calculated as rhein is a mandatory component of rhubarb root powder.

When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX2) 'Prolonged use may cause serious bowel problems'; and

- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).

When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:

- (LAX1) 'Drink plenty of water' (or words to that effect).

When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and

- (LAX4) 'This product may have laxative effect'.

When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX1) 'Drink plenty of water' (or words to that effect); and

- (LAX2) 'Prolonged use may cause serious bowel problems'.

 

4279

RHUS AROMATICA

A, E, H

 

4280

RHUS CHINENSIS

A, H

 

4281

RHUS GLABRA

A, E, H

 

4282

RHUS VENENATA

H

Only for use as an active homoeopathic ingredient.

 

4283

RIBES GROSSULARIA

A, E, H

 

4284

RIBES NIGRUM

A, E, H

 

4285

RIBOFLAVIN

A, E

 

4286

RIBOFLAVIN SODIUM PHOSPHATE

A, E

When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:

- (SODIUM) ‘The recommended daily dose of this medicine contains [state quantity and units] of sodium (or words to that effect).’

 

4287

RIBOFLAVIN TETRAACETATE

E

Only for use in topical medicines for dermal application.

 

4288

RIBOFLAVINE

A, E

 

4289

RIBOFLAVINE SODIUM PHOSPHATE

A, E

 

4290

RIBONUCLEIC ACID

E

Only for use in topical medicines for dermal application.

 

4291

RIBOSE

A

Only for use in oral medicines.

When the medicine is for oral ingestion and the total amount of all sugars (monosaccharides and disaccharides such as glucose, honey, invert sugar, lactose, maltose, and sucrose) is more than 100mg in the maximum daily dose, then the medicine requires the following warning statement on the medicine label:

- (SUGARS) ‘Contains [insert name of sugar]’ if medicine contains one sugar OR ‘Contains sugars' (or words to that effect) if medicine contains two or more sugars.

If one of the sugars is lactose then the medicine also requires the following warning statement on the medicine label:

- (LACT) ‘Contains lactose' (or words to that effect).

 

4292

RICE

E

 

4293

RICE BRAN

E

 

4294

RICE BRAN OIL

E

 

4295

RICE BRAN WAX

A, E, H

 

4296

RICE STARCH

E

 

4297

RICE VINEGAR

E

 

4298

RICE WINE

E

Ethanol is a mandatory component of Rice wine.

When the concentration of ethanol in the medicine is more than 3%, the medicine requires the following warning statement on the medicine label:

- (ETHAN) ‘Contains ethanol’ or ‘contains alcohol’

 

4299

RICINOLEIC ACID

E

Only for use in topical medicines for dermal application.

 

4300

RICINUS COMMUNIS

A, H

Only for use when the plant part must be seed and the plant preparation is oil fixed.

 

4301

ROBINIA PSEUDOACACIA

A, E, H

When the herbal substance is derived from plant parts other than the leaf or flower, the maximum recommended daily dose of the medicine must be no more than 1mg of the dry herbal material.

 

4302

ROHDEA JAPONICA

A, H

The maximum recommended daily dose must be no more than the equivalent of 1mg of the dry herbal material.

 

4303

ROSA ARVENSIS

A, E, H

 

4304

ROSA CANINA

A, E, H

 

4305

ROSA CYMOSA

A, E, H

 

4306

ROSA EGLANTERIA

A, E, H

 

4307

ROSA GALLICA

A, E, H

 

4308

ROSA LAEVIGATA

A, E, H

 

4309

ROSA MULTIFLORA

A, E, H

 

4310

ROSA ROXBURGHII FRUIT EXTRACT

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.002%.

 

4311

ROSA RUGOSA

A, E, H

 

4312

ROSA VILLOSA

A, E, H

 

4313

ROSA X CENTIFOLIA

A, E, H

 

4314

ROSA X DAMASCENA

A, E, H

 

4315

ROSANA

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4316

ROSE ABSOLUTE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4317

ROSE FRUIT FRESH

A, E, H

 

4318

ROSE HIP

E

 

4319

ROSE OIL

A, E, H

 

4320

ROSE OXIDE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4321

ROSEMARY OIL

A, E, H

Safrole is a mandatory component of Rosemary oil.

When for internal use then the concentration of safrole in the medicine must be no more than 0.1%.

When for topical use then the concentration of safrole in the medicine must be no more than 1%.

 

4322

ROSMARINUS OFFICINALIS

A, E, H

Camphor and cineole are mandatory components of Rosmarinus officinalis.

In solid and semi solid preparations, the concentration of camphor must be no more than 12.5%.

In liquid preparations other than essential oils or distillates, the concentration of camphor must be no more than 2.5%.

When the concentration of cineole in the preparation is more than 25%, the nominal capacity of the container must not be more than 25 millilitres.

In liquid preparations other than essential oils or distillates, when the concentration of cineole in the preparation is more than 25% and the nominal capacity of the container is more than 15 millilitres but less than or equal to 25 millilitres, the medicine must have a child resistant closure and restricted flow insert fitted on the container and include the following warning statements on the medicine label:

- (CHILD) 'Keep out of reach of children' (or words to that effect); and

- (NTAKEN) 'Not to be taken'.

In liquid preparations other than essential oils or distillates, when the concentration of cineole in the preparation is more than 25% and the nominal capacity of the container is no more than 15 millilitres, the medicine must have a restricted flow insert fitted on the container and include the following warning statements on the medicine label:

- (CHILD) 'Keep out of reach of children' (or words to that effect); and

- (NTAKEN) 'Not to be taken'.

If the concentration of camphor is more than 2.5%, the nominal capacity of the container must be no more than 25 millilitres.

 

 

 

4323

ROYAL JELLY

A, E

10-Hydroxy-2-decenoic acid is a mandatory component of Royal jelly.

The medicine requires the following warning statements on the medicine label:

- (CHILD2) 'Not suitable for children'

- (ROYJ) 'Not to be taken by asthma and allergy sufferers' in 3 mm type, prominent on front and 'This product contains royal jelly which has been reported to cause severe allergic reactions and in rare cases fatalities, especially in asthma and allergy sufferers'.

 

4324

ROYAL JELLY FRESH

A, E

10-Hydroxy-2-decenoic acid is a mandatory component of Royal jelly fresh.

The medicine requires the following warning statements on the medicine label:

- (CHILD2) 'Not suitable for children'

- (ROYJ) 'Not to be taken by asthma and allergy sufferers' in 3 mm type, prominent on front and 'This product contains royal jelly which has been reported to cause severe allergic reactions and in rare cases fatalities, especially in asthma and allergy sufferers'.

 

4325

ROYAL JELLY LYOPHILISED

A, E

10-Hydroxy-2-decenoic acid is a mandatory component of Royal jelly lyophilised.

The medicine requires the following warning statements on the medicine label:

- (CHILD2) 'Not suitable for children'

- (ROYJ) 'Not to be taken by asthma and allergy sufferers' in 3 mm type, prominent on front and 'This product contains royal jelly which has been reported to cause severe allergic reactions and in rare cases fatalities, especially in asthma and allergy sufferers'.

 

4326

RUBBER NATURAL

E

Only for use in topical medicines for dermal application.

 

4327

RUBIA CORDIFOLIA

A, H

 

4328

RUBIA TINCTORUM

A, H

 

4329

RUBUS CHINGII

A, H

 

4330

RUBUS CORCHORIFOLIUS

A, H

 

4331

RUBUS COREANUS

A, E, H

 

4332

RUBUS FRUTICOSUS

A, E, H

 

4333

RUBUS IDAEUS

A, E, H

 

4334

RUBUS OCCIDENTALIS

A, E, H

 

4335

RUBUS PARVIFOLIUS

A, H

 

4336

RUBUS ROSIFOLIUS

A, H

 

4337

RUDBECKIA HIRTA

A, H

 

4338

RUE OIL

A, H

 

4339

RUM

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4340

RUMEX ACETOSA

A, H

 

4341

RUMEX ACETOSELLA

A, H

 

4342

RUMEX CONGLOMERATUS

A, H

 

4343

RUMEX CRISPUS

A, E, H

 

4344

RUMEX PULCHER

A, H

 

4345

RUMEX SCUTATUS

A, H

 

4346

RUSCUS ACULEATUS

A, H

 

4347

RUTA GRAVEOLENS

A, E, H

 

4348

RUTOSIDE

A, E

 

4349

RYE

E

Gluten is a mandatory component of Rye when the route of administration is other than topical and mucosal.

When the route of administration is other than topical or mucosal, the medicine requires the following warning statement on the medicine label:

- (GLUTEN) 'Contains [insert name of ingredient]' (or words to that effect).

 

4350

RYE BRAN

E

Gluten is a mandatory component of Rye bran when the route of administration is other than topical and mucosal.

When the route of administration is other than topical or mucosal, the medicine requires the following warning statement on the medicine label:

- (GLUTEN) 'Contains [insert name of ingredient]' (or words to that effect).

 

4351

S-ISOPROPYL 3-METHYLTHIOCROTONATE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4352

SABINENE HYDRATE

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4353

SACCHARIDE ISOMERATE

E

Only for use in topical medicines for dermal application and not to be included in medicines for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 3.66%.

 

4354

SACCHARIN

E

The medicine requires the following warning statement on the medicine label:

- (SACCH) 'Contains saccharin' (or words to that effect).

 

4355

SACCHARIN SODIUM

E

The medicine requires the following warning statement on the medicine label:

- (SACCH) 'Contains saccharin' (or words to that effect).

When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:

- (SODIUM) ‘The recommended daily dose of this medicine contains [state quantity and units] of sodium (or words to that effect).’

 

4356

SACCHAROMYCES CEREVISIAE

A, E

When for topical use, the concentration in the medicine must be no more than 1%.

 

4357

SACCHAROMYCES CEREVISIAE (BOULARDII)

A

 

4358

SACCHAROMYCES CERVISIAE POLYSACCHARIDES

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 1%.

 

4359

SACCHAROMYCES/ZINC FERMENT

E

Only for use in topical medicines for dermal application.

 

4360

SACCHARUM OFFICINARUM

A, E, H

 

4361

SAFFLOWER OIL

A, E, H

 

4362

SAFFRON

E

Permitted for use only as a colour for either topical use or with an oral route of administration.

 

4363

SAGE LEAF DRY

A, E, H

Thujone is a mandatory component of Sage leaf dry.

The concentration of thujone in the medicine must be no more than 4%.

 

4364

SAGE LEAF POWDER

A, H

Thujone is a mandatory component of Sage leaf powder.

The concentration of thujone in the medicine must be no more than 4%.

 

4365

SAGE OIL DALMATIAN

A

Thujone is a mandatory component of Sage oil dalmatian.

The concentration of thujone in the medicine must be no more than 4%.

When the concentration of Sage oil dalmatian in the medicine is more than 10% and the nominal capacity of the container is no more than 15 mL, a restricted flow insert and child resistant closure must be  fitted on the container and the medicine requires the following warning statements on the medicine label:

- (CHILD) ‘Keep out of reach of children’ (or word to that effect)

- (NTAKEN) ‘Not to be taken’

 

4366

SAGE OIL SPANISH

A, E, H

 

4367

SALICORNIA EUROPAEA EXTRACT

E

Only for use in topical medicines for dermal use and not to be included in medicines intended for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 0.002%.

 

4368

SALICYLALDEHYDE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4369

SALICYLIC ACID

E, H

Only for use in topical medicines for dermal application.

The concentration in the medicine must be no more than 40%.

 

 

4370

SALIX ALBA

A, E, H

 

4371

SALIX DAPHNOIDES

A, H

 

4372

SALIX DISCOLOR

A, H

 

4373

SALIX FRAGILIS

A, H

 

4374

SALIX NIGRA

A, H

 

4375

SALIX PURPUREA

A, H

 

4376

SALSOLA KALI

A, H

 

4377

SALVIA CHINENSIS

A, H

 

4378

SALVIA FRUTICOSA

A, H

 

4379

SALVIA HISPANICA

A, E, H

 

4380

SALVIA LAVANDULAEFOLIA

A, H

 

4381

SALVIA MILTIORRHIZA

A, H

 

4382

SALVIA OFFICINALIS

A, E, H

Thujone is a mandatory component of Salvia officinalis.

The concentration of thujone in the medicine must be no more than 4%.

 

4383

SALVIA SCLAREA

A, E, H

 

4384

SAMBUCUS CANADENSIS

A, H

 

4385

SAMBUCUS EBULUS

A, H

 

4386

SAMBUCUS NIGRA

A, E, H

 

4387

SANDALWOOD OIL EAST INDIAN

A, E, H

 

4388

SANGUINARIA CANADENSIS

H

Only for use as an active homoeopathic ingredient.

The potency must be more than 4X.

 

 

4389

SANICULA EUROPAEA

A, H

 

4390

SANTALUM ALBUM

A, E, H

 

4391

SANTALUM SPICATUM

A, E, H

The route of administration must be topical or inhalation.

The plant preparation must be oil.

The plant part must be root or stem wood including heartwood.

 

4392

SAPINDUS MUKOROSSI

A, H

 

4393

SAPONARIA OFFICINALIS

A, H

 

4394

SAPOSHNIKOVIA DIVARICATA

A, H

 

4395

SARCOSINE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.5%.

 

4396

SARGASSUM FUSIFORME

A, H

Iodine is a mandatory component of Sargassum fusiforme.

Only for external use when the concentration of iodine in the medicine (excluding salts derivatives or iodophors) is 2.5% or less.

Only for internal use when the medicine contains less than 300 micrograms of iodine per maximum recommended daily dose.

 

 

4397

SARGASSUM SILIQUASTRUM

A, H

Iodine is a mandatory component of Sargassum siliquastrum.

Only for external use when the concentration of iodine in the medicine (excluding salts derivatives or iodophors) is 2.5% or less.

Only for internal use when the medicine contains less than 300 micrograms of iodine per maximum recommended daily dose.

 

4398

SASSAFRAS ALBIDUM

A, H

Safrole is a mandatory component of Sassafras albidum.

When for internal use then the concentration of safrole in the medicine must be no more than 0.1%.

When for topical use then the concentration of safrole in the medicine must be no more than 1%.

 

4399

SATUREIA HORTENSIS

A, H

 

4400

SATUREIA MONTANA

A, H

 

4401

SAUROPUS SPATULIFOLIUS

A, H

 

4402

SAURURUS CHINENSIS

A, H

 

4403

SAUSSUREA COSTUS

A, H

 

4404

SAVORY OIL SUMMER

A, H

 

4405

SAXIFRAGA GRANULATA

A, E, H

 

4406

SAXIFRAGA STOLONIFERA

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must not be more than 0.0816%.

 

4407

SCAPHIUM SCAPHIGERUM

A, H

 

4408

SCHEFFLERA HEPTAPHYLLA

A, H

 

4409

SCHINOPSIS QUEBRACHO-COLORADO

A, H

 

4410

SCHINUS MOLLE

A, H

 

4411

SCHINUS MOLLE OIL

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4412

SCHISANDRA CHINENSIS

A, E, H

 

4413

SCHIZONEPETA TENUIFOLIA

A, E, H

 

4414

SCHOENOCAULON OFFICINALE

A, H

The maximum recommended daily dose must contain no more than the equivalent of 1mg of the dry herbal material.

 

4415

SCLAREOL

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4416

SCLAREOLIDE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4417

SCLERANTHUS ANNUUS

A, H

 

4418

SCLEROTIUM GUM

E

Only for use in topical medicines for dermal application.

 

4419

SCOPOLIA CARNIOLICA

A, H

The concentration of equivalent dry Scopolia carniolica in the medicine must be no more than 10mg/Kg or 10mg/L or 0.001%.

 

4420

SCROPHULARIA NINGPOENSIS

A, H

 

4421

SCROPHULARIA NODOSA

A, H

 

4422

SCURRULA PARASITICA VAR. GRACILIFLORA

A, H

 

4423

SCUTELLARIA BAICALENSIS

A, E, H

 

4424

SCUTELLARIA BARBATA

A, H

 

4425

SCUTELLARIA LATERIFLORA

A, E, H

 

4426

SEA WHIP EXTRACT

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.02%.

 

4427

SEC BUTYL 3-METHYLBUT-2-ENETHIOATE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4428

SEC-BUTYL THIOISOVALERATE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4429

SECALE CEREALE

A, H

Gluten is a mandatory component of Secale cereale when the plant part is seed and the route of administration is other than topical and mucosal.

When the route of administration is other than topical or mucosal, the medicine requires the following warning statement on the medicine label:

- (GLUTEN) 'Contains [insert name of ingredient]' (or words to that effect).

 

4430

SEDUM ACRE

A, H

 

4431

SELAGINELLA TAMARISCINA

A, H

 

4432

SELENICEREUS GRANDIFLORUS

A, E, H

 

4433

SELENIUM

H

Only for use as an active homoeopathic ingredient.

Oral medicines must contain no more than 150 micrograms of selenium per maximum recommended daily dose.

When for oral use, the medicine requires the following warning statement on the medicine label:

- (SELE) 'This medicine contains selenium which is toxic in high doses.

A daily dose of 150 micrograms for adults of selenium from dietary supplements should not be exceeded.'

 

4434

SELENOCYSTEINE

A

Selenium is a mandatory component of Selenocysteine for oral and sublingual use.

Oral medicines must contain no more than 150 micrograms of selenium per maximum recommended daily dose.

When for oral use, the medicine requires the following warning statement on the medicine label:

- (SELE) 'This medicine contains selenium which is toxic in high doses.

 A daily dose of 150 mcg for adults of selenium from dietary supplements should not be exceeded.'

 

4435

SELENOMETHIONINE

A

Selenium is a mandatory component of Selenomethionine for oral and sublingual use.

Oral medicines must contain no more than 150 micrograms of selenium per maximum recommended daily dose.

When for oral use, the medicine requires the following warning statement on the medicine label:

- (SELE) 'This medicine contains selenium which is toxic in high doses. A daily dose of 150 micograms for adults of selenium from dietary supplements should not be exceeded.’

 

4436

SELF-EMULSIFYING GLYCERYL MONOSTEARATE

E

 

4437

SEMECARPUS ANACARDIUM

A, H

When the plant part is other than seed, the maximum recommended daily dose must be no more than 1mg of the equivalent dry herbal material.

 

4438

SEMOLINA

E

 

4439

SEMPERVIVUM TECTORUM

A, H

 

4440

SENEGA ROOT DRY

A, H

 

4441

SENEGA ROOT POWDER

A, H

 

4442

SENNA ALEXANDRINA

A, H

When for oral or sublingual use, Hydroxyanthracene glycosides calculated as sennoside B is a mandatory component of Senna alexandrina.

When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX2) 'Prolonged use may cause serious bowel problems'; and

- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).

When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:

- (LAX1) 'Drink plenty of water' (or words to that effect).

When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and

- (LAX4) 'This product may have laxative effect'.

When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX1) 'Drink plenty of water' (or words to that effect); and

- (LAX2) 'Prolonged use may cause serious bowel problems'.

 

4443

SENNA FRUIT ALEXANDRIAN DRY

A, H

When for oral or sublingual use, Hydroxyanthracene glycosides calculated as sennoside B is a mandatory component of Senna fruit alexandrian dry.

When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX2) 'Prolonged use may cause serious bowel problems'; and

- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).

When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:

- (LAX1) 'Drink plenty of water' (or words to that effect).

When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and

- (LAX4) 'This product may have laxative effect'.

When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX1) 'Drink plenty of water' (or words to that effect); and

- (LAX2) 'Prolonged use may cause serious bowel problems'.

 

4444

SENNA FRUIT ALEXANDRIAN POWDER

A, H

When for oral or sublingual use, Hydroxyanthracene glycosides calculated as sennoside B is a mandatory component of Senna fruit alexandrian powder.

When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX2) 'Prolonged use may cause serious bowel problems'; and

- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).

When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:

- (LAX1) 'Drink plenty of water' (or words to that effect).

When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and

- (LAX4) 'This product may have laxative effect'.

When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX1) 'Drink plenty of water' (or words to that effect); and

- (LAX2) 'Prolonged use may cause serious bowel problems'.

 

4445

SENNA FRUIT TINNEVELLY DRY

A, H

When for oral or sublingual use, Hydroxyanthracene glycosides calculated as sennoside B is a mandatory component of Senna fruit tinnevelly dry.

When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX2) 'Prolonged use may cause serious bowel problems'; and

- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).

When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:

- (LAX1) 'Drink plenty of water' (or words to that effect).

When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and

- (LAX4) 'This product may have laxative effect'.

When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX1) 'Drink plenty of water' (or words to that effect); and

- (LAX2) 'Prolonged use may cause serious bowel problems'.

 

4446

SENNA FRUIT TINNEVELLY POWDER

A, H

When for oral or sublingual, Hydroxyanthracene glycosides calculated as sennoside B is a mandatory component of Senna fruit tinnevelly powder.

When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX2) 'Prolonged use may cause serious bowel problems'; and

- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).

When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:

- (LAX1) 'Drink plenty of water' (or words to that effect).

When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and

- (LAX4) 'This product may have laxative effect'.

When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX1) 'Drink plenty of water' (or words to that effect); and

- (LAX2) 'Prolonged use may cause serious bowel problems'.

 

4447

SENNA LEAF DRY

A, H

When for oral or sublingual use, Hydroxyanthracene glycosides calculated as sennoside B is a mandatory component of Senna leaf dry.

When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX2) 'Prolonged use may cause serious bowel problems'; and

- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).

When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:

- (LAX1) 'Drink plenty of water' (or words to that effect).

When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]';

- (LAX4) 'This product may have laxative effect'.

When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX1) 'Drink plenty of water' (or words to that effect); and

- (LAX2) 'Prolonged use may cause serious bowel problems'.

 

4448

SENNA LEAF POWDER

A, H

When for oral or sublingual use, Hydroxyanthracene glycosides calculated as sennoside B is a mandatory component of Senna Leaf Powder.

When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX2) 'Prolonged use may cause serious bowel problems'; and

- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).

When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:

- (LAX1) 'Drink plenty of water' (or words to that effect).

When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and

- (LAX4) 'This product may have laxative effect'.

When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX1) 'Drink plenty of water' (or words to that effect); and

- (LAX2) 'Prolonged use may cause serious bowel problems'.

 

4449

SENNA OCCIDENTALIS

A, H

Hydroxyanthracene glycosides calculated as sennoside B is a mandatory component of Senna occidentalis when the route of administration is oral administration.

When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX2) 'Prolonged use may cause serious bowel problems'; and

- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' [or words to that effect].

When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:

- (LAX1) 'Drink plenty of water' [or words to that effect].

When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and

- (LAX4) 'This product may have laxative effect'.

When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended;

- (LAX1) 'Drink plenty of water' [or words to that effect]; and

- (LAX2) 'Prolonged use may cause serious bowel problems'.

 

4450

SENNA TORA

A, H

When for oral or sublingual use, Hydroxyanthracene glycosides calculated as sennoside B is a mandatory component of Senna tora.

When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX2) 'Prolonged use may cause serious bowel problems'; and

- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' (or words to that effect).

When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:

- (LAX1) 'Drink plenty of water' (or words to that effect).

When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and

- (LAX4) 'This product may have laxative effect'.

When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX1) 'Drink plenty of water' (or words to that effect); and

- (LAX2) 'Prolonged use may cause serious bowel problems'.

 

4451

SEPIA

H

Only for use as an active homoeopathic ingredient. 

 

4452

SEQUOIA SEMPERVIRENS

A, H

 

4453

SEQUOIADENDRON GIGANTEUM

A, H

 

4454

SERENOA REPENS

A, H

 

4455

SERINE

A, E

 

4456

SERUM ANGUILLAE

H

Only for use as an active homoeopathic ingredient. 

 

4457

SESAME OIL

A, E, H

 

4458

SESAME SEED

E

 

4459

SESAMUM INDICUM

A, E, H

 

4460

SETARIA ITALICA

A, H

 

4461

SHARK CALCIUM CHONDROITIN SULFATE

A

 

4462

SHARK CARTILAGE

A, E

The medicine requires the following warning statement on the medicine label:

- (SHARK) 'Children, pregnant or breastfeeding women, and those who have recently had a heart attack, surgery or a major accident should not consume this product without medical advice' (or words to that effect)

 

4463

SHARK CHONDROITIN SULFATE

A

 

4464

SHARK POTASSIUM CHONDROITIN SULFATE

A

 

4465

SHARK SODIUM CHONDROITIN SULFATE

A

 

4466

SHARK-LIVER OIL

A, E

Vitamin A and Colecalciferol are mandatory components of Shark-liver oil.

When for internal use, the maximum recommended daily dose must be no more than 25 micrograms of Vitamin D.

When for use in topical medicines, the concentration of Vitamin A in the medicine must be no more than 1%.

When for internal use, the maximum daily dose must be no more than 3000 micrograms of Retinol Equivalents.

When preparations for internal use in adults contain more than 33 micrograms of retinol equivalents per dosage unit in divided preparations or per gram of an undivided preparation, the medicine requires the following warning statements on the medicine label:

- (VITA2) ‘WARNING: If you are pregnant - or considering becoming pregnant - do not take vitamin A supplements without consulting your doctor or pharmacist [or words to that effect].’ NOTE: Position this warning at the beginning of the directions for use.

- (VITA4) ‘WARNING - When taken in excess of 3000 micrograms retinol equivalents - vitamin A can cause birth defects.’ NOTE: Position this warning at the beginning of the directions for use.

- (VITA3) ‘The recommended daily amount of vitamin A from all sources is 700 micrograms retinol equivalents for women and 900 micrograms retinol equivalents for men.’

 

4467

SHEA BUTTER

E

 

4468

SHEA BUTTER UNSAPONIFIABLES

E

Only for use in topical medicines for dermal application.

 

4469

SHELLAC

E

 

4470

SHEPHERD'S PURSE HERB DRY

A, H

 

4471

SHEPHERD'S PURSE HERB POWDER

A, H

 

4472

SHERRY WINE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4473

SIGESBECKIA ORIENTALIS

A, E, H

 

4474

SILICA

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4475

SILICA DIMETHYL SILYLATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 4%.

 

4476

SILICA SILYLATE

E

Only for use in topical medicines for dermal application.

 

4477

SILICIFIED MICROCRYSTALLINE CELLULOSE

E

Only for use when the route of administration is other than inhalation.

 

4478

SILICON DIOXIDE

A, E, H

Only for use when the route of administration is other than inhalation.

 

4479

SILICONE QUATERNIUM-8

E

Only for use in wash-off topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 2.5%.

The medicine requires the following warning statement on the medicine label:

- (EYE) 'Avoid contact with eyes' (or words to that effect).

 

4480

SILVER

H

Only for use as an active homoeopathic ingredient. 

The concentration in the medicine must be no more than 1%.

 

4481

SILVER BEET

E, H

 

4482

SILVER BOROSILICATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine should be no more than 0.6%.  

Silver is a mandatory component of Silver borosilicate when the route of administration is topical.

The concentration of silver in the medicine must be no more than 1%.

 

4483

SILVER NITRATE

H

Only for use as an active homoeopathic ingredient. 

 

4484

SILYBUM MARIANUM

A, E, H

 

4485

SIMABA CEDRON

A, H

 

4486

SIMETHICONE

E

 

4487

SIMMONDSIA CHINENSIS

A, E, H

 

4488

SINAPIS ALBA

A, H

Allyl isothiocyanate is a mandatory component of Sinapis alba when the plant part is seed.

The concentration of allyl isothiocyanate from all ingredients in the product must be no more than 10 mg/kg or 10 mg/L or 0.001%.

 

4489

SINAPIS ARVENSIS

A, H

 

4490

SINOMENIUM ACUTUM

A, H

 

4491

SIPHONESTEGIA CHINENSIS

A, H

 

4492

SIRAITIA GROSVENORII

A, E, H

 

4493

SISYMBRIUM OFFICINALE

A, H

 

4494

SKATOLE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4495

SKIPJACK-LIVER OIL

A, E

Vitamin A and Colecalciferol are mandatory components of Shark-liver oil.

When for internal use, the maximum recommended daily dose must be no more than 25 micrograms of Vitamin D.

When for use in topical medicines, the concentration of Vitamin A in the medicine must be no more than 1%.

When for internal use, the maximum daily dose must be no more than 3000 micrograms of Retinol Equivalents.

When preparations for internal use in adults contain more than 33 micrograms of retinol equivalents per dosage unit in divided preparations or per gram of an undivided preparation, the medicine requires the following warning statements on the medicine label:

- (VITA2) ‘WARNING: If you are pregnant - or considering becoming pregnant - do not take vitamin A supplements without consulting your doctor or pharmacist [or words to that effect].’ NOTE: Position this warning at the beginning of the directions for use.

- (VITA4) ‘WARNING - When taken in excess of 3000 micrograms retinol equivalents - vitamin A can cause birth defects.’ NOTE: Position this warning at the beginning of the directions for use.

- (VITA3) ‘The recommended daily amount of vitamin A from all sources is 700 micrograms retinol equivalents for women and 900 micrograms retinol equivalents for men.’

 

4496

SLIPPERY ELM BARK DRY

A, H

 

4497

SLIPPERY ELM BARK POWDER

A, E, H

 

4498

SMILAX ARISTOLOCHIIFOLIA

A, H

 

4499

SMILAX CHINA

A, H

 

4500

SMILAX GLABRA

A, H

 

4501

SMILAX OFFICINALIS

A, E, H

 

4502

SMILAX ORNATA

A, E, H

 

4503

SMOKE EXTRACT

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4504

SODIUM ACETATE

E

When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:

- (SODIUM) ‘The recommended daily dose of this medicine contains [state quantity and units] of sodium (or words to that effect).’

 

4505

SODIUM ACETYLATED HYALURONATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 1%.

 

4506

SODIUM ACID CITRATE

A, E, H

When used as an active ingredient, only for use in oral medicines.

When used as an active, only for use in oral medicines.

When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:

- (SODIUM) ‘The recommended daily dose of this medicine contains [state quantity and units] of sodium (or words to that effect).’

 

4507

SODIUM ACRYLATES COPOLYMER

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.8%.

 

4508

SODIUM ACRYLATES CROSSPOLYMER-2

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 0.7 % (w/w).

 

4509

SODIUM ACRYLOYDIMETHYLTAURATE/VP CROSSPOLYMER

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 2% (w/w).

 

4510

SODIUM ALGINATE

E

 

4511

SODIUM ASCORBATE

A, E, H

When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:

- (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium (or words to that effect).'

 

4512

SODIUM ASCORBYL PHOSPHATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

When used in a sunscreen, the concentration in the medicine must be no more than 0.1%.

 When used in products other than sunscreens, the concentration in the medicine must be no more than 0.5%.

 

4513

SODIUM ASCORBYL/CHOLESTERYL PHOSPHATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 5%.

 

4514

SODIUM BENZOATE

E

Medicines containing benzoates require the following warning statement on the medicine label:

- (TBNZO8) ‘Contains benzoates' (or words to this effect) if the medicine contains two or more benzoate sources or ‘Contains [insert the approved name of benzoate used]’ (or words to this effect) if product contains one benzoate source.

When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:

- (SODIUM) ‘The recommended daily dose of this medicine contains [state quantity and units] of sodium (or words to that effect).’

 

4515

SODIUM BETA-HYDROXY-BETA-METHYLBUTYRATE

A, H

When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:

- (SODIUM) ‘The recommended daily dose of this medicine contains [state quantity and units] of sodium’ (or words to that effect).

 

4516

SODIUM BETA-HYDROXY-BETA-METHYLBUTYRATE MONOHYDRATE

A, H

 

4517

SODIUM BICARBONATE

A, E

When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:

- (SODIUM) ‘The recommended daily dose of this medicine contains [state quantity and units] of sodium (or words to that effect).'

When used as an active ingredient, the medicine may only be for oral rehydration salts in powdered and effervescent tablet dosage forms.

Medicines for use as oral rehydration therapy are subject to the following conditions:

a) the medicine complies with the requirements specified in the British Pharmacopoeia, as in force or existing from time to time, for Oral Rehydration Salts;

b) the sodium content and total osmolarity of the solution after it has been prepared according to the instructions on the packet are consistent with the criteria specified by the World Health Organisation (WHO) and the United Nations Childrens Fund (UNICEF) in the document 'Expert consultation on oral rehydration salts formulation 18 July 2001.'

c) the medicine requires the following warning statements on the medicine label:

- (UOAD) 'Use only as directed.'

- (DIAR) 'If diarrhoea persists for more than 6 hours in infants under 6 months - 12 hours in children under 3 years - 24 hours in children aged 3-6 years or 48 hours in adults and children over 6 years - seek medical advice (or words to that effect).'

- (DIAR3) 'If diarrhoea persists, seek medical advice.'

 

4518

SODIUM BISULFITE

E

When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:

- (SODIUM) ‘The recommended daily dose of this medicine contains [state quantity and units] of sodium’ (or words to that effect).

Medicines containing sulfites salts require the following warning statement on the medicine label:

- (SULF) 'Contains sulfites' (or words to this effect) if medicine contains two or more sulfite sources or 'Contains (insert the approved name of sulfites used)' (or words to this effect) if medicine contains one sulfite source.

 

4519

SODIUM BROMIDE

H

Only for use as an active homoeopathic ingredient.

 

4520

SODIUM C14-16 OLEFIN SULFONATE

E

Only for use in topical medicines for dermal application.

 

4521

SODIUM CARBOMER

E

Only for use as an excipient in topical medicines for dermal application.

 

4522

SODIUM CARBONATE

E

When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:

- (SODIUM) ‘The recommended daily dose of this medicine contains [state quantity and units] of sodium’ (or words to that effect).

 

4523

SODIUM CARBONATE MONOHYDRATE

E

When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:

- (SODIUM) ‘The recommended daily dose of this medicine contains [state quantity and units] of sodium (or words to that effect).'

 

4524

SODIUM CARBOXYMETHYL BETAGLUCAN

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.005%.

 

4525

SODIUM CARRAGEENAN

E

 

4526

SODIUM CASEINATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4527

SODIUM CETOSTEARYL SULFATE

E

Only for use in topical medicines for dermal application.

 

4528

SODIUM CHLORIDE

A, E, H

When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:

- (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium' (or words to that effect).

When used in a solid preparation, the pH of a 10 g/L aqueous solution must not be more than 11.5.

When used in a liquid or a semi-solid preparation, the pH of the preparation must not exceed 11.5.

 

4529

SODIUM CHONDROITIN SULFATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.001%.

 

4530

SODIUM CITRATE

A, E

Only for oral use when used as an active ingredient.

When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:

- (SODIUM) ‘The recommended daily dose of this medicine contains [state quantity and units] of sodium’ (or words to that effect).

 

4531

SODIUM CITRATE DIHYDRATE

A, E

Only for oral use when used as an active ingredient.

When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:

- (SODIUM) ‘The recommended daily dose of this medicine contains [state quantity and units] of sodium’ (or words to that effect).

 

4532

SODIUM COCO PG-DIMONIUM CHLORIDE PHOSPHATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.05%.

 

4533

SODIUM COCOAMPHOACETATE

E

Only for use in topical medicines for dermal application.

 

4534

SODIUM COCOYL SARCOSINATE

E

Only for use in topical medicines for dermal application.

 

4535

SODIUM CYCLAMATE

E

When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:

- (SODIUM) ‘The recommended daily dose of this medicine contains [state quantity and units] of sodium’ (or words to that effect).

 

4536

SODIUM DEHYDROACETATE

E

Only for use in topical medicines for dermal application.

 

4537

SODIUM DNA

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. 

The concentration in the medicine must be no more than 0.1%.

 

4538

SODIUM DODECYLBENZENESULFONATE

E

Only for use in topical medicines for dermal application.

The concentration in the medicine must be no more than 30%.

 

4539

SODIUM ERYTHORBATE

E

When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:

- (SODIUM) ‘The recommended daily dose of this medicine contains [state quantity and units] of sodium’ (or words to that effect).

 

4540

SODIUM ETHYL HYDROXYBENZOATE

E

 

4541

SODIUM FLUORIDE

A, E, H

Fluoride is a mandatory component of Sodium fluoride.

Only for use when the route of administration is dental and the dosage form is pastes, powders or gels for dental hygiene.

When used as an active ingredient, it is subject to the following conditions:

a) Only for use in combination with at least one other listable therapeutically active ingredient.

b) The concentration of fluoride ion must be no more than 1,500 mg/kg.

When the concentration of fluoride ion is more than 1000 mg/kg, the medicine requires the following statements on the medicine label:

- (DNTSW) 'Do not swallow.'

- (CHILD4) 'Do not use [this product/insert name of product]  in children 6 years of age or less.'

When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:

- (SODIUM) ‘The recommended daily dose of this medicine contains [state quantity and units] of sodium (or words to that effect).'

 

4542

SODIUM FUMARATE

E

When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:

- (SODIUM) ‘The recommended daily dose of this medicine contains [state quantity and units] of sodium’ (or words to that effect).

 

4543

SODIUM GLYCEROPHOSPHATE

A, E, H

When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:

- (SODIUM) ‘The recommended daily dose of this medicine contains [state quantity and units] of sodium (or words to that effect).'

 

4544

SODIUM HYALURONATE

E

Only for use in topical medicines for dermal application.

 

4545

SODIUM HYDROGENATED TALLOW GLUTAMATE

E

Only for use in topical medicines for dermal application.

 

4546

SODIUM HYDROXIDE

E

The concentration in the medicine must be no more than 5%.

When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:

- (SODIUM) ‘The recommended daily dose of this medicine contains [state quantity and units] of sodium’ (or words to that effect).

When used in a solid preparation, the pH of a 10 g/L aqueous solution must not be more than 11.5.

When used in a liquid or a semi-solid preparation, the pH of the preparation must not exceed 11.5.

 

4547

SODIUM HYDROXYCITRATE

A

 

4548

SODIUM HYDROXYETHYL ACRYLATE/ACRYLOYLDIMETHYL TAURATE COPOLYMER

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 1.5%.

 

4549

SODIUM HYDROXYMETHYLGLYCINATE

E

Only for use in topical medicines for dermal application.

 

4550

SODIUM HYPOCHLORITE

E

Chlorine is a mandatory component of Sodium hypochlorite.

The concentration of chlorine in the medicine must be no more than 4%.

When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:

- (SODIUM) ‘The recommended daily dose of this medicine contains [state quantity and units] of sodium’ (or words to that effect).

 

4551

SODIUM ISOSTEAROYL LACTYLATE

E

Only for use in topical medicines for dermal application.

 

4552

SODIUM LACTATE

E

When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:

- (SODIUM) ‘The recommended daily dose of this medicine contains [state quantity and units] of sodium’ (or words to that effect).

 

4553

SODIUM LAURETH SULFATE

E

When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:

- (SODIUM) ‘The recommended daily dose of this medicine contains [state quantity and units] of sodium’ (or words to that effect).

 

4554

SODIUM LAUROAMPHOACETATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 5%.

 

4555

SODIUM LAUROYL METHYL ISETHIONATE

E

Only for use in wash-off topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 11%.

 

4556

SODIUM LAUROYL SARCOSINATE

E

Only for use in topical medicines for dermal application.

 

4557

SODIUM LAURYL PHOSPHATE

E

When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:

- (SODIUM) ‘The recommended daily dose of this medicine contains [state quantity and units] of sodium’ (or words to that effect).

 

4558

SODIUM LAURYL SULFATE

E

When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:

- (SODIUM) ‘The recommended daily dose of this medicine contains [state quantity and units] of sodium’ (or words to that effect).

 

4559

SODIUM LAURYL SULFOACETATE

E

Only for use in topical medicines for dermal application.

 

4560

SODIUM MAGNESIUM SILICATE

E

Only for use in topical medicines for dermal application.

 

4561

SODIUM MANNOSE PHOSPHATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.5%.

 

4562

SODIUM METABISULFITE

E

When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:

- (SODIUM) ‘The recommended daily dose of this medicine contains [state quantity and units] of sodium’ (or words to that effect).

Medicines containing sulfites salts require the following warning statement on the medicine label:

- (SULF) 'Contains sulfites' (or words to this effect) if medicine contains two or more sulfite sources or 'Contains (insert the approved name of sulfites used)' (or words to this effect) if medicine contains one sulfite source.

 

4563

SODIUM METAPHOSPHATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or damaged skin.

The concentration in the medicine must not be more than 0.1%.

 

4564

SODIUM METHYL COCOYL TAURATE

E

Only for dental use.

The concentration in the medicine must be no more than 2%.

 

4565

SODIUM METHYL HYDROXYBENZOATE

E

When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:

- (SODIUM) ‘The recommended daily dose of this medicine contains [state quantity and units] of sodium’ (or words to that effect).

Medicines containing hydroxybenzoates require the following warning statement on the medicine label:

- (TOTBNZ) ‘Contains hydroxybenzoates’ (or words to this effect) if the medicine contains more than one hydroxybenzoate source OR ‘Contains [insert the approved name of hydroxybenzoate used]’ (or words to this effect) if product contains one hydroxybenzoate source.

 

4566

SODIUM MOLYBDATE DIHYDRATE

A

Only for use in oral medicines.

Molybdenum is a mandatory component of Sodium molybdate dihydrate.

The percentage of molybdenum from sodium molybdate dihydrate should be calculated based on the molecular weight of sodium molybdate dihydrate.

The maximum daily dose of molybdenum from Sodium molybdate dihydrate must be no more than 125 micrograms.

 

4567

SODIUM MONOFLUOROPHOSPHATE

A

Fluoride is a mandatory component of sodium monofluorophosphate.

Only for use when the route of administration is dental and the dosage form is pastes, powders or gels for dental hygiene.

When used as an active ingredient, it is subject to the following conditions:

a) Only for use in combination with at least one other listable therapeutically active ingredient.

b) The concentration of fluoride ion must be no more than 1,500 mg/kg.

When the concentration of fluoride ion is more than 1000 mg/kg, the medicine requires the following statements on the medicine label:

- (DNTSW) 'Do not swallow.'

- (CHILD4) 'Do not use [this product/insert name of product]  in children 6 years of age or less.'

When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:

- (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium (or words to that effect).'

 

4568

SODIUM MYRISTOYL GLUTAMATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. 

The concentration in the medicine must be no more than 0.0164%.

 

4569

SODIUM NITRATE

H

Only for use as an active homoeopathic ingredient.

 

4570

SODIUM NONOXYNOL-4 SULFATE

E

Only for use in topical medicines for dermal application.

 

4571

SODIUM PANTOTHENATE

A, E, H

When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:

- (SODIUM) ‘The recommended daily dose of this medicine contains [state quantity and units] of sodium’ (or words to that effect).

 

4572

SODIUM PCA

E

Only for use in topical medicines for dermal application.

 

4573

SODIUM PERBORATE

A, H

Boron is a mandatory component of sodium perborate.

When for internal use, the maximum recommended daily dose must not provide more than 6 mg of boron.

When used preparations for dermal use, which are not for paediatric or antifungal use, the concentration of boron from all ingredients in the product must not exceed 3500 mg/kg or 3500 mg/L or 0.35%.

When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:

- (SODIUM) ‘The recommended daily dose of this medicine contains [state quantity and units] of sodium (or words to that effect).'

 

4574

SODIUM PERCARBONATE

E

Only for use in topical medicines for dermal application.

The concentration in the medicine must be no more than 15%.

 

4575

SODIUM POLYACRYLATE

E

Only for use in topical medicines for dermal application.

 

4576

SODIUM POLYACRYLATE STARCH

E

Only to be used in a medicine where Procter & Gamble Australia Pty Ltd (Client ID 11364), who applied to have the ingredient included in this Determination, is the sponsor of the medicine or has given written authorisation to the sponsor of a medicine to include the ingredient in the medicine. This paragraph ceases to be a requirement for this ingredient after 27 September 2020.

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must not be more than 1%.

 

4577

SODIUM POLYMETAPHOSPHATE

E

 

4578

SODIUM PROPIONATE

E

Only for use in topical medicines for dermal application.

 

4579

SODIUM PROPYL HYDROXYBENZOATE

E

When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:

- (SODIUM) ‘The recommended daily dose of this medicine contains [state quantity and units] of sodium’ (or words to that effect).

Medicines containing hydroxybenzoates require the following warning statement on the medicine label:

- (TOTBNZ) ‘Contains hydroxybenzoates’ (or words to this effect) if the medicine contains more than one hydroxybenzoate source OR ‘Contains [insert the approved name of hydroxybenzoate used]’ (or words to this effect) if product contains one hydroxybenzoate source.

 

4580

SODIUM RNA

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.2%.

 

4581

SODIUM SELENATE

A, H

Selenium is a mandatory component of sodium selenate.

Oral medicines must contain no more than 150 micrograms of selenium per maximum recommended daily dose.

When for oral use, the medicine requires the following warning statement on the medicine label:

- (SELE) 'This medicine contains selenium which is toxic in high doses. A daily dose of 150 micrograms for adults of selenium from dietary supplements should not be exceeded.'

 

 

4582

SODIUM SELENATE DECAHYDRATE

A

Selenium is a mandatory component of sodium selenate decahydrate.

Oral medicines must contain no more than 150 micrograms of selenium per maximum recommended daily dose.

When for oral use, the medicine requires the following warning statement on the medicine label:

- (SELE) 'This medicine contains selenium which is toxic in high doses. A daily dose of 150 micrograms for adults of selenium from dietary supplements should not be exceeded.'

 

 

4583

SODIUM SELENITE

A, H

Selenium is a mandatory component of Sodium selenite.

Oral medicines must contain no more than 150 micrograms of selenium per maximum recommended daily dose.

When for oral use, the medicine requires the following warning statement on the medicine label:

- (SELE) 'This medicine contains selenium which is toxic in high doses. A daily dose of 150 micrograms for adults of selenium from dietary supplements should not be exceeded.’

 

 

4584

SODIUM SELENITE PENTAHYDRATE

A

Selenium is a mandatory component of Sodium selenite pentahydrate.

Oral medicines must contain no more than 150 micrograms of selenium per maximum recommended daily dose.

When for oral use, the medicine requires the following warning statement on the medicine label:

- (SELE) 'This medicine contains selenium which is toxic in high doses. A daily dose of 150 micrograms for adults of selenium from dietary supplements should not be exceeded.’

 

 

4585

SODIUM SILICATE

E

When used in a solid preparation, the pH of a 10 g/L aqueous solution must not be more than 11.5.

When used in a liquid or a semi-solid preparation, the pH of the preparation must not exceed 11.5.

When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:

- (SODIUM) ‘The recommended daily dose of this medicine contains [state quantity and units] of sodium’ (or words to that effect).

 

4586

SODIUM STARCH GLYCOLLATE

E

When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:

- (SODIUM) ‘The recommended daily dose of this medicine contains [state quantity and units] of sodium’ (or words to that effect).

 

4587

SODIUM STARCH GLYCOLLATE TYPE A

E

When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:

- (SODIUM) ‘The recommended daily dose of this medicine contains [state quantity and units] of sodium’ (or words to that effect).

 

4588

SODIUM STEARATE

E

Only for use in topical medicines for dermal application.

 

4589

SODIUM STEAROXY PG-HYDROXYETHYLCELLULOSE SULFONATE

E

Only for use in topical medicines for dermal application and not to be used in topical medicines intended for use in the eye.

The concentration in the medicine must be no more than 2%.

 

4590

SODIUM STEAROYL GLUTAMATE

E

Only for use in topical medicines for dermal application and not to be used in topical medicines intended for use in the eye.

The concentration in the medicine must be no more than 2.5%.

 

4591

SODIUM STEAROYL LACTYLATE

E

Only for use in topical medicines for dermal application.

 

4592

SODIUM STEARYL PHTHALAMATE

E

Only for use in medicines for dermal application and not to be used in topical medicines intended for use in the eye.

The concentration in the medicine must be no more than 1.5%.

 

4593

SODIUM SUCCINATE

E

Only for use in topical medicines for dermal application.

 

4594

SODIUM SULFATE

A, E, H

When it is not intended to be a laxative, the medicine requires the following warning statement on the medicine label:

- (LAX4) 'Substance may have a laxative effect'.

When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:

- (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium' (or words to that effect).

 

4595

SODIUM SULFATE DECAHYDRATE

A, E, H

When it is not intended to be a laxative, the medicine requires the following warning statement on the medicine label:

- (LAX4) 'Substance may have a laxative effect'.

When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:

- (SODIUM) 'The recommended daily dose of this medicine contains [state quantity and units] of sodium' (or words to that effect).

 

4596

SODIUM SULFITE

E

When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:

- (SODIUM) ‘The recommended daily dose of this medicine contains [state quantity and units] of sodium’ (or words to that effect).

Medicines containing sulfites salts require the following warning statement on the medicine label:

- (SULF) 'Contains sulfites' (or words to this effect) if medicine contains two or more sulfite sources or 'Contains (insert the approved name of sulfites used)' (or words to this effect) if medicine contains one sulfite source.

 

4597

SODIUM SULFITE HEPTAHYDRATE

E

Only for use in topical medicines for dermal application.

Medicines containing sulfites salts require the following warning statement on the medicine label:

- (SULF) 'Contains sulfites' (or words to this effect) if medicine contains two or more sulfite sources or 'Contains (insert the approved name of sulfites used)' (or words to this effect) if medicine contains one sulfite source.

 

4598

SODIUM TRIPOLYPHOSPHATE

E

Only for use when the route of administration is topical for dermal application, mucous membrane (buccal mucosa) or dental.

Not to be included in topical medicines intended for use in the eye.

The concentration in the medicine must be no more than 5%.

 

4599

SOLANUM DULCAMARA

A, H

When for internal use, steroidal alkaloids calculated as solanine is a mandatory component of Solanum dulcamara.

When for internal use, the maximum recommended daily dose must not provide more than 10mg of steroidal alkaloids calculated as solanine.

 

4600

SOLANUM FEROX

A, H

When for internal use, steroidal alkaloids calculated as solanine is a mandatory component of Solanum ferox.

When for internal use, the maximum recommended daily dose must not provide more than 10mg of steroidal alkaloids calculated as solanine.

 

4601

SOLANUM LYCOCARPUM FRUIT EXTRACT

E

Only for use in topical medicines for dermal use and not to be included in topical medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.02%.

 

4602

SOLANUM MELONGENA

A, H

When for internal use, steroidal alkaloids calculated as solanine is a mandatory component of Solanum melongena.

When for internal use, the maximum recommended daily dose must not provide more than 10mg of steroidal alkaloids calculated as solanine.

 

4603

SOLANUM NIGRUM

A, H

When for internal use, steroidal alkaloids calculated as solanine is a mandatory component of Solanum nigrum.

When for internal use, the maximum recommended daily dose must not provide more than 10mg of steroidal alkaloids calculated as solanine.

 

4604

SOLANUM TUBEROSUM

A, H

When for internal use, steroidal alkaloids calculated as solanine is a mandatory component of Solanum tuberosum.

When for internal use, the maximum recommended daily dose must not provide more than 10mg of steroidal alkaloids calculated as solanine.

 

4605

SOLIDAGO GIGANTEA

A, H

 

4606

SOLIDAGO GIGANTEA MIS

A, E, H

 

4607

SOLIDAGO VIRGAUREA

A, E, H

 

4608

SOLUBLE MAIZE STARCH

E

 

4609

SOLUBLE POTATO STARCH

E

 

4610

SOLVENT GREEN 3

E

Permitted for use only as a colour for topical use.

 

4611

SOLVENT RED 1

E

Permitted for use only as a colour for topical use.

 

4612

SOLVENT VIOLET 13

E

Permitted for use only as a colour for topical use.

 

4613

SOLVENT YELLOW 172

E

Permitted for use only as a colour for topical use.

The concentration in the medicine must be no more than 0.3%.

 

4614

SOLVENT YELLOW 33

E

Permitted for use only as a colour for topical use.

 

4615

SOPHORA FLAVESCENS

A, E, H

 

4616

SOPHORA TONKINENSIS

A, H

 

4617

SORBIC ACID

E

The medicine requires the following warning statement on the medicine label:

- (SORB8) 'Contains sorbates' (or word to this effect) if medicine contains two or more sorbate sources OR 'Contains [insert the approved name of sorbate source used]' (or words to this effect) if medicine contains one sorbate source.

 

4618

SORBITAN ISOSTEARATE

E

Only for use in topical medicines for dermal application.

 

4619

SORBITAN MONO-OLEATE

E

 

4620

SORBITAN MONOLAURATE

E

 

4621

SORBITAN MONOSTEARATE

E

 

4622

SORBITAN OLEATE

E

 

4623

SORBITAN OLIVATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 10%.

 

4624

SORBITAN PALMITATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 2%.

 

4625

SORBITAN SESQUIISOSTEARATE

E

Only for use in topical medicines for dermal application.

 

4626

SORBITAN SESQUIOLEATE

E

Only for use in topical medicines for dermal application.

 

4627

SORBITAN STEARATE

E

 

4628

SORBITAN TRISTEARATE

E

Only for use in topical medicines for dermal application.

 

4629

SORBITOL

A, E

When used as an active ingredient, can only be supplied as an uncompounded medicine substance packed for retail sale, and must comply with an uncompounded substance monograph of the British Pharmacopoeia, as in force or existing from time to time.

When the quantity of sugar alcohols per maximum recommended daily dose is more than 2 grams, the quantity of the sugar alcohols must be declared on the label and the medicine requires the following warning statement on the medicine label:

- (SUGOLS) ‘Products containing [insert name of sugar alcohol(s)] may have a laxative effect or cause diarrhoea' (or words to that effect).

 

4630

SORBITOL SOLUTION (70 PER CENT) (CRYSTALLISING)

A, E

Sorbitol is a mandatory component of Sorbitol solution (70 per cent) (crystallising).

When used as an active ingredient, can only be supplied as an uncompounded medicine substance packed for retail sale, and must comply with an uncompounded substance monograph of the British Pharmacopoeia, as in force or existing from time to time.

When the quantity of sugar alcohols per maximum recommended daily dose is more than 2 grams, the quantity of the sugar alcohols must be declared on the label and the medicine requires the following warning statement on the medicine label:

- (SUGOLS) ‘Products containing [insert name of sugar alcohol(s)] may have a laxative effect or cause diarrhoea (or words to that effect).'

 

 

4631

SORBITOL SOLUTION (70 PER CENT) (NON-CRYSTALLISING)

A, E

Sorbitol is a mandatory component of Sorbitol solution (70 per cent) (non-crystallising).

When used as an active ingredient, can only be supplied as an uncompounded medicine substance packed for retail sale, and must comply with an uncompounded substance monograph of the British Pharmacopoeia, as in force or existing from time to time.

When the quantity of sugar alcohols per maximum recommended daily dose is more than 2 grams, the quantity of the sugar alcohols must be declared on the label and the medicine requires the following warning statement on the medicine label:

- (SUGOLS) ‘Products containing [insert name of sugar alcohol(s)] may have a laxative effect or cause diarrhoea (or words to that effect).'

 

4632

SORBUS AUCUPARIA

A, H

 

4633

SORBUS DOMESTICA

A, H

 

4634

SORGHUM

E

 

4635

SORGHUM VULGARE

A, H

 

4636

SOY PHOSPHATIDYLSERINE-ENRICHED SOY LECITHIN LIQUID

A

Soy phosphatidylserine is a mandatory component of soy phosphatidylserine-enriched soy lecithin liquid.

The concentration of soy phosphatidylserine in the medicine must be no more than 15%.

 

4637

SOY PHOSPHATIDYLSERINE-ENRICHED SOY LECITHIN POWDER

A

Soy phosphatidylserine is a mandatory component of soy phosphatidylserine-enriched soy lecithin powder.

The concentration of soy phosphatidylserine in the medicine must be no more than 15%.

 

4638

SOY POLYSACCHARIDE

E

 

4639

SOY PROTEIN

E

 

4640

SOY STEROL

E

 

4641

SOYA BEAN

E

 

4642

SOYA BRAN

E

 

4643

SOYA OIL

A, E, H

 

4644

SOYBEAN FLOUR

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4645

SOYBEAN GLYCERIDES

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 4%.

 

4646

SPARGANIUM STOLONIFERUM

A, H

 

4647

SPARTIUM JUNCEUM

A, H

 

4648

SPATHOLOBUS SUBERECTUS

A, H

 

4649

SPEARMINT OIL

A, E, H

When the ingredient is included in a medicine that is listed in the Register:

- on or after 1 July 2018, the medicine must comply with all requirements under (a)-(c);

- before 1 July 2018 and supplied on or after 1 January 2020, the medicine must comply with all requirements under (a)-(c); or

- before 1 July 2018 and supplied before 1 January 2020, the medicine may comply with requirements under (a)-(c).

a) Menthol is a mandatory component of spearmint oil.

b) When the medicine is for topical use:

(i) the medicine must not be intended for use in the eye or on damaged skin;

(ii) the maximum concentration of menthol must not exceed 5%; and

(iii) the following warning statements are required on the medicine label:

- (SKTEST) If you have sensitive skin, test this product on a small area of skin before applying it to a large area;

- (IRRIT) If irritation develops, discontinue use; and

- (EYE) Avoid contact with eyes (or words to that effect).

c) When the medicine is for internal use, the maximum recommended daily dose must not contain more than 1 gram of menthol.

 

4650

SPEARMINT OIL TERPENELESS

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

Menthol is a mandatory component of spearmint oil terpeneless.

When the medicine is for topical use:

a) the medicine must not be intended for use in the eye or on damaged skin;

b) the maximum concentration of menthol must not exceed 5%; and

c) the medicine requires the following warning statements on the medicine label:

- (SKTEST) If you have sensitive skin, test this product on a small area of skin before applying it to a large area;

- (IRRIT) If irritation develops, discontinue use; and

- (EYE) Avoid contact with eyes (or words to that effect).

When the medicine is for internal use, the maximum recommended daily dose must not contain more than 1 gram of menthol.

 

4651

SPHINGOLIPIDS

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.1%.

 

4652

SPIGELIA ANTHELMIA

A, H

 

4653

SPIGELIA MARILANDICA

A, H

The maximum recommended daily dose must be no more than the equivalent of 1mg of the dry herbal material.

 

4654

SPIKE LAVENDER OIL

A, E, H

Camphor is a mandatory component of spike lavender oil.

In solid and semi solid preparations, the concentration of camphor must be no more than 12.5%.

In liquid preparations other than essential oils, the concentration of camphor must be no more than 2.5%.

In essential oil preparations, if the concentration of camphor is more than 2.5% but less than or equal to 10%, and the nominal capacity of the container is less than 25 millilitres, the medicine must have a restricted flow insert fitted on the container and include the following warning statements on the medicine label:

- (CHILD) 'Keep out of reach of children' (or words to that effect); and

- (NTAKEN) 'Not to be taken'.

In essential oil preparations, if the concentration of camphor is more than 10%, and the nominal capacity of the container is less than 15 millilitres, the medicine must have a restricted flow insert fitted on the container and include the following warning statements on the medicine label:

- (CHILD) 'Keep out of reach of children' (or words to that effect); and

- (NTAKEN) 'Not to be taken'.

In essential oil preparations, if the concentration of camphor is more than 10%, and the nominal capacity of the container is more than 15 millilitres but less than or equal to 25 millilitres, the medicine must have a restricted flow insert and child resistant closure fitted on the container and include the following warning statements on the medicine label:

- (CHILD) 'Keep out of reach of children' (or words to that effect); and

- (NTAKEN) 'Not to be taken'.

If the concentration of camphor is more than 2.5%, the nominal capacity of the container must be no more than 25 millilitres.

 

4655

SPINACH

E

 

4656

SPINACIA OLERACEA

A, E, H

 

4657

SPIRODELA POLYRRHIZA

A, H

 

4658

SPIRULINA

E

 

4659

SPRAY-DRIED GLUCOSE SYRUP

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4660

SPRAY-DRIED LIQUID GLUCOSE

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4661

SPRUCE OIL

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4662

SQUALANE

E

Only for use in topical medicines for dermal application.

 

4663

SQUALENE

A, E

 

4664

SQUID OIL

A

Only for use in oral medicines.

The medicine requires the following warning statement on the medicine label:

- (SFOOD) 'Derived from seafood'.

Must be obtained from species of the order Teuthida of the class Cephalopoda, be used in combination with other ingredients in the medicine and be presented in a therapeutic dosage form for therapeutic use.

 

4665

SQUILL DRY

A, H

 

4666

SQUILL INDIAN DRY

A, H

 

4667

SQUILL INDIAN POWDER

A, H

 

4668

SQUILL POWDER

A, H

 

4669

ST JOHN'S WORT DRY EXTRACT QUANTIFIED

A

When used for oral ingestion, the medicine requires the following warning statement on the medicine label:

- (STJOHN) 'St John's Wort affects the way many prescription medicines work - including oral contraceptives. Consult your doctor.'

 

4670

ST JOHN'S WORT HERB DRY

A, H

When used for oral ingestion, the medicine requires the following warning statement on the medicine label:

- (STJOHN) 'St John's Wort affects the way many prescription medicines work - including oral contraceptives. Consult your doctor.'

 

4671

ST JOHN'S WORT HERB POWDER

A, H

When used for oral ingestion, the medicine requires the following warning statement on the medicine label:

- (STJOHN) 'St John's Wort affects the way many prescription medicines work - including oral contraceptives. Consult your doctor.'

 

4672

STACHYS OFFICINALIS

A, E, H

 

4673

STACHYS PALUSTRIS

A, H

 

4674

STACHYURUS HIMALAICUS

A, H

 

4675

STANNIC OXIDE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.005%.

 

4676

STANNOUS CHLORIDE

H

Only for use as an active homoeopathic ingredient. 

 

4677

STAR ANISE OIL

A, E

When the concentration in the medicine is more than 50% and the nominal capacity of the container is equal to or less than 50mL, a restricted flow insert must be fitted on the container and the medicine requires the following warning statement on the medicine label:

- (CHILD) ‘Keep out of reach of children’ (or words to that effect).

 

4678

STARCH

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4679

STARCH SODIUM OCTENYL SUCCINATE

E

 

4680

STEARALKONIUM CHLORIDE

E

Only for use in topical medicines for dermal application.

 

4681

STEARALKONIUM HECTORITE

E

Only for use in topical medicines for dermal application.

 

4682

STEARAMIDE

E

Only for use in topical medicines for dermal application.

 

4683

STEARAMIDOETHYL DIETHYLAMINE

E

Only for use in topical medicines for dermal application.

 

4684

STEARAMIDOPROPYL DIMETHYLAMINE

E

Only for use in topical medicines for dermal application.

 

4685

STEARAMIDOPROPYL PG-DIMONIUM CHLORIDE PHOSPHATE

E

Only for use in topical medicines for dermal application.

The concentration in the medicine must be no more than 2%.

When the medicine is intended to be used on the eye, the medicine requires the following warning statement on the medicine label:

- (EYE2) 'May be irritant to the eyes' (or words to that effect).

 

4686

STEARETH-10

E

Only for use in topical medicines for dermal application.

 

4687

STEARETH-100

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 1.5%.

 

4688

STEARETH-2

E

Only for use in topical medicines for dermal application.

 

4689

STEARETH-20

E

Only for use in topical medicines for dermal application.

 

4690

STEARETH-21

E

Only for use in topical medicines for dermal application.

 

4691

STEARETH-5

E

Only for use in topical medicines for dermal application.

 

4692

STEARIC ACID

E

 

4693

STEAROPTENES

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4694

STEAROXY DIMETHICONE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 4%.

 

4695

STEAROXYTRIMETHYLSILANE

E

Only for use in topical medicines for dermal application.

 

4696

STEAROYL MACROGOLGLYCERIDES

E

Only for use in oral medicines.

The concentration in the medicine must be no more than 0.6%.

 

4697

STEARYL ACETATE

E

Only for use in topical medicines for dermal application.

 

4698

STEARYL ALCOHOL

E

 

4699

STEARYL DIMETHICONE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 4.5%.

The medicine requires the following warning statements on the medicine label:

- (EYE2) 'May be irritant to the eyes' (or words to that effect)

- (EYE) 'Avoid contact with eyes' (or words to that effect).

 

4700

STEARYL GLYCYRRHETINATE

E

Only for use in topical medicines for dermal application.

 

4701

STEARYL HEPTANOATE

E

Only for use in topical medicines for dermal application.

 

4702

STEARYL MYRISTATE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4703

STEARYL STEARATE

E

Only for use in topical medicines for dermal application.

 

4704

STELLARIA CHAMAEJASME

A, H

 

4705

STELLARIA DICHOTOMA

A, H

 

4706

STELLARIA MEDIA

A, E, H

 

4707

STEMONA JAPONICA

A, H

 

4708

STEMONA SESSILIFOLIA

A, H

 

4709

STENOTAPHRUM SECUNDATUM

A, H

 

4710

STEPHANIA TETRANDA

A, H

 

4711

STERCULIA

A, H

 

4712

STERCULIA TRAGACANTHA

A, H

 

4713

STERCULIA URENS

A, H

 

4714

STEVIA REBAUDIANA

A, E, H

 

4715

STEVIOL GLYCOSIDES

E

Only for use in oral medicines.

 

4716

STILLINGIA SYLVATICA

A, H

 

4717

STORAX PREPARED

A, E, H

 

4718

STRAWBERRY

E

 

4719

STRAWBERRY ESSENCE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4720

STREPTOCOCCUS SALIVARIUS

A

Permitted for use in only oral medicines and only when the strain of Streptococcus salivarius is confirmed to be K12.

The name of strain must be declared on the label.

The following warning statement is required on the medicine label:

- (CHILD5) 'Use in children under 3 years is not recommended'.

 

4721

STREPTOCOCCUS THERMOPHILUS

A

 

4722

STROBILANTHES CUSIA

A, H

 

4723

STRONG AMMONIA SOLUTION

E

Ammonia is a mandatory component of dilute ammonia solution.

The concentration of ammonia in the medicine must be no more than 0.5%.

When for internal use, the concentration in the medicine must be no more than 0.25%.

 

4724

STRONTIUM CARBONATE

H

Only for use as an active homoeopathic ingredient. 

 

4725

STROPHANTHUS GRATUS

H

Only for use as an active homoeopathic ingredient.

 

4726

STROPHANTHUS HISPIDUS

H

Only for use as an active homoeopathic ingredient.

 

4727

STRYCHNOS IGNATII

H

Only for use as an active homoeopathic ingredient. 

Strychnine (of Strychnos spp.) is a mandatory component of Strychnos ignatii.

The concentration of Strychnine (of Strychnos spp.) must be no more than 1 milligram/Kg or 1 milligram/L or 0.1%.

 

4728

STRYCHNOS NUX-VOMICA

A, H

Strychnine (of Strychnos spp.) is a mandatory component of Strychnos nux-vomica.

The concentration of Strychnine (of Strychnos spp.) must be no more than 1 milligram/Kg or 1 milligram/L or 0.1%.

 

4729

STYPHNOLOBIUM JAPONICUM

A, E, H

 

4730

STYRAX BENZOIN

A, E, H

 

4731

STYRAX OIL

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4732

STYRAX PARALLELONEURUM

A, H

 

4733

STYRAX TONKINENSIS

A, H

 

4734

STYRENE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4735

STYRENE/ACRYLATES COPOLYMER

E

Only for use in topical medicines for dermal application.

 

4736

STYROLYL ACETATE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4737

SUBLIMED SULFUR

H

Only for use as an active homoeopathic ingredient. 

 

4738

SUCCINIC ACID

E

 

4739

SUCRALOSE

E

 

4740

SUCROSE

E

When the medicine is for oral ingestion and the total amount of all sugars (monosaccharides and disaccharides such as glucose, honey, invert sugar, lactose, maltose, and sucrose) is more than 100mg in the maximum daily dose, then the medicine requires the following warning statement on the medicine label:

- (SUGARS) ‘Contains [insert name of sugar]’ if medicine contains one sugar OR ‘Contains sugars' (or words to that effect) if medicine contains two or more sugars.

If one of the sugars is lactose then the medicine also requires the following warning statement on the medicine label:

- (LACT) ‘Contains lactose' (or words to that effect).

 

4741

SUCROSE ACETATE ISOBUTYRATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4742

SUCROSE ACETATE PALMITATE STEARATE

E

Only for use in topical medicines for dermal application and not intended for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 0.3%.

 

4743

SUCROSE COCOATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 2%.

 

4744

SUCROSE DISTEARATE

E

Only for use in topical medicines for dermal application.

 

4745

SUCROSE LAURATE

E

When for oral or sublingual use, Sucrose is a mandatory component of Sucrose laurate.

When the medicine is for oral ingestion and the total amount of all sugars (monosaccharides and disaccharides such as glucose, honey, invert sugar, lactose, maltose, and sucrose) is more than 100mg in the maximum daily dose, then the medicine requires the following warning statement on the medicine label:

- (SUGARS) ‘Contains [insert name of sugar]’ if medicine contains one sugar OR ‘Contains sugars' (or words to that effect) if medicine contains two or more sugars.

If one of the sugars is lactose then the medicine also requires the following warning statement on the medicine label:

- (LACT) ‘Contains lactose' (or words to that effect).

 

4746

SUCROSE OCTAACETATE

E

When for oral or sublingual use, sucrose is a mandatory component of sucrose octaacetate.

When the medicine is for oral ingestion and the total amount of all sugars (monosaccharides and disaccharides such as glucose, honey, invert sugar, lactose, maltose, and sucrose) is more than 100mg in the maximum daily dose, then the medicine requires the following warning statement on the medicine label:

- (SUGARS) ‘Contains [insert name of sugar]’ if medicine contains one sugar OR ‘Contains sugars' (or words to that effect) if medicine contains two or more sugars.

If one of the sugars is lactose then the medicine also requires the following warning statement on the medicine label:

- (LACT) ‘Contains lactose' (or words to that effect).

 

4747

SUCROSE PALMITATE

E

Only for use in topical medicines for dermal application.

 

4748

SUCROSE POLYCOTTONSEEDATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

 The concentration in the medicine must be no more than 1%.

The medicine requires the following warning statements on the medicine label:

- (EYE) 'Avoid contact with the eyes' (or words to that effect)

- (EYE2) 'May be irritant to the eyes' (or words to that effect).

 

4749

SUCROSE STEARATE

E

For use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

When for topical use, the concentration in the medicine must be no more than 0.25%.

For oral use as a manufacturing aid only.

When for oral use, the concentration in the medicine must be no more than 0.2 mg per dosage unit.

 

4750

SUCROSE TRISTEARATE

E

Only for use in topical medicines for dermal application and not to be included in medicines for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 2%.

 

 

4751

SUDAN III

E

Permitted for use only as a colour for topical use.

 

4752

SUGAR CANE WAX ALCOHOLS

A, H

The maximum recommended daily dose must not provide more than 12mg.

The medicine requires the following warning statements on the medicine label:

- (PREGNT) 'Not recommended for use by pregnant and lactating women' (or words to that effect).

 

4753

SUGARCANE

E, H

When for oral or sublingual use, sucrose is a mandatory component of Sugarcane.

When the medicine is for oral ingestion and the total amount of all sugars (monosaccharides and disaccharides such as glucose, honey, invert sugar, lactose, maltose, and sucrose) is more than 100mg in the maximum daily dose, then the medicine requires the following warning statement on the medicine label:

- (SUGARS) ‘Contains [insert name of sugar]’ if medicine contains one sugar OR ‘Contains sugars' (or words to that effect) if medicine contains two or more sugars.

If one of the sugars is lactose then the medicine also requires the following warning statement on the medicine label:

- (LACT) ‘Contains lactose' (or words to that effect).

 

4754

SULFATED CASTOR OIL

E

Only for use in topical medicines for dermal application.

 

4755

SULFATED LOW MOLECULAR WEIGHT FUCANS

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.025%.

 

4756

SULFUR DIOXIDE

E

Medicines containing sulfites salts require the following warning statement on the medicine label:

- (SULF) 'Contains sulfites' (or words to this effect) if medicine contains two or more sulfite sources or 'Contains (insert the approved name of sulfites used)' (or words to this effect) if medicine contains one sulfite source.

 

4757

SULFUR IODIDE

H

Only for use as an active homoeopathic ingredient. 

 

4758

SULFURIC ACID

E, H

Only for use as an active homoeopathic ingredient or excipient ingredient. 

The concentration in the medicine must be no more than 0.5%.

 

4759

SULFURISED 1-METHYL-4-(1-METHYLETHENYL)-CYCLOHEXENE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4760

SULISOBENZONE

A

Only for use as an active ingredient in sunscreens for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 10%.

When used in primary sunscreen products and listed in the Register on or after 1 January 2018, the medicine must have the following statements on the medicine label:

- (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and

- (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).

When used in primary sunscreen products and listed in the Register before 1 January 2018, the medicine requires the following statements on the medicine label if supplied after 1 July 2019:

- (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and

- (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).

 

4761

SULISOBENZONE SODIUM

A

Only for use as an active ingredient in sunscreens for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 10%.

When used in primary sunscreen products and listed in the Register on or after 1 January 2018, the medicine must have the following statements on the medicine label:

- (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and

- (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).

When used in primary sunscreen products and listed in the Register before 1 January 2018, the medicine requires the following statements on the medicine label if supplied after 1 July 2019:

- (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and

- (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).

 

4762

SUNFLOWER OIL

A, E, H

 

4763

SUNFLOWER SEED

E, H

 

4764

SUNSET YELLOW FCF

E

Permitted for use only as a colour for either topical use or with an oral route of administration.

 

 

4765

SUNSET YELLOW FCF ALUMINIUM LAKE

E

Permitted for use only as a colour for oral and topical use.

 

4766

SUPEROXIDE DISMUTASE

E

Only for use in topical medicines for dermal application.

 

4767

SWEDE

E

 

4768

SWEET ORANGE OIL TERPENES AND TERPENOIDS

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4769

SWEET POTATO

E

 

4770

SWERTIA CHIRATA

A, H

 

4771

SWIETENIA MAHOGANI

A, H

 

4772

SYAGRUS ROMANZOFFIANA

A, E, H

 

4773

SYMPHYTUM OFFICINALE

H

When used orally as an active homoeopathic ingredient, the concentration must be a dilution of 12X or more.

When used in topical medicines for dermal application, the concentration in the preparation must be no more than 10mg/kg or 10mg/L or 0.001%.

 

4774

SYMPLOCARPUS FOETIDUS

A, H

 

4775

SYNTHETIC BEESWAX

E

Only for use in topical medicines for dermal applications.

 

4776

SYNTHETIC TERPENE RESIN

E

Only for use in topical, oral or oral application medicines.

When the route of administration is oral, the dosage form must be chewing gum.

 

4777

SYNTHETIC WAX

E

 

4778

SYRINGA RETICULATA

A, H

 

4779

SYRINGA VULGARIS

A, H

 

4780

SYZYGIUM AROMATICUM

A, E, H

When the plant preparation is oil or distillate and the concentration of this oil or distillate in the product is greater than 25%, the nominal capacity of the container must be no more than 25 millilitres and the medicine must include the following warning statements on the medicine label: - (CHILD) 'Keep out of reach of children' (or words to that effect); and - (NTAKEN) 'Not to be taken'.

When the plant preparation is oil or distillate, the concentration of this oil or distillate in the medicine is greater than 25% and the nominal capacity of the container is more than 15 millilitres but less than or equal to 25 millilitres, a child resistant closure and restricted flow insert must be fitted on the container.

When the plant preparation is oil or distillate, the concentration of oil or distillate in the product is greater than 25% and the nominal capacity of the container is less than 15 millilitres, a restricted flow insert must be fitted on the container.

When the plant preparation is oil or distillate and the preparation is for topical use in the mouth, the preparation may not contain more than 5 millilitres of the oil or distillate and the concentration of oil or distillate in the product must not be greater than 25%.

 

4781

SYZYGIUM CUMINI

A, H

 

4782

SYZYGIUM JAMBOS

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must not be more than 0.0693%.

 

4783

TABEBUIA SERRATIFOLIA

A, E, H

 

4784

TAGETES ERECTA

A, H

 

4785

TAGETES MINUTA

A, E, H

 

4786

TAGETES OIL

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4787

TAIPAN SNAKE

H

Only for use as an active homoeopathic ingredient.

 

4788

TALLOW

E

Only for use in topical medicines for dermal application.

 

4789

TALLOW GLYCERIDES

E

 

4790

TAMARINDUS INDICA

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4791

TAMARIX APHYLLA

A, H

 

4792

TAMARIX CHINENSIS

A, H

 

4793

TAMARIX GALLICA

A, H

 

4794

TAMUS COMMUNIS

A, H

If the plant part is fruit or root, the maximum recommended daily dose must be no more than 1mg of the equivalent dry fruit or dry root of Tamus communis.

 

4795

TANACETUM CINERARIIFOLIUM

A, H

The concentration in the medicine must be no more than 10%.

 

4796

TANACETUM PARTHENIUM

A, E, H

 

4797

TANACETUM VULGARE

A, H

Oil (of Tanacetum vulgare) is a mandatory component of Tanacetum vulgare.

The concentration of oil (of Tanacetum vulgare) in the medicine must be no more than 0.8%.

 

4798

TANGERINE OIL

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4799

TANGERINE OIL COLDPRESSED

A, E, H

When used internally, oxedrine is a mandatory component of tangerine oil coldpressed.

The quantity of oxedrine in the maximum recommended daily dose must be no more than 30 milligrams.

 

4800

TANNIC ACID

E

 

4801

TAPIOCA STARCH

E

 

4802

TARAXACUM MONGOLICUM

A, E, H

 

4803

TARAXACUM OFFICINALE

A, E, H

 

4804

TARO

E

 

4805

TARRAGON OIL

A, E, H

 

4806

TARTARIC ACID

E

 

4807

TARTRAZINE

E

Permitted for use only as a colour for oral and topical use.

The medicine requires the following warning statement on the medicine label:

- (TART) 'Contains tartrazine' (or words to that effect).

 

4808

TARTRAZINE ALUMINIUM LAKE

E

Permitted for use only as a colour for oral and topical use.

The medicine requires the following warning statement on the medicine label:

- (TART) 'Contains tartrazine' (or words to that effect).

 

4809

TASMANNIA LANCEOLATA

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4810

TAURINE

A, E

 

4811

TEA-STEARATE

E

Only for use in topical medicines for dermal application.

 

4812

TERMINALIA ARJUNA

A

Only for use in oral medicines.

Only for use when the plant part is bark.

The maximum recommended daily dose must be no more than 6 grams of Terminalia arjuna dried bark or its extract equivalents.

The medicine requires the following warning statements on the medicine label:

- (PREGNT) 'Not recommended for use by pregnant and lactating women' (or words to that effect)

- (CHILD2) 'Not suitable for children'.

 

4813

TERMINALIA BELLIRICA

A

Only for use when the preparation is as an aqueous extract of the fruit pericarp.

 

4814

TERMINALIA CATAPPA

A, H

 

4815

TERMINALIA CHEBULA

A, H

 

4816

TERMINALIA FERDINANDIANA

A, E, H

Only for use when the plant part is fruit flesh, fruit flesh dry or the preparation is as an aqueous extract of the fruit flesh.

When used as an excipient, the ingredient is only for use in topical medicines for dermal application and not to be included in medicines intended for use on damaged skin or in the eye.

When used as an excipient, the concentration in the medicine must be no more than 0.3%.

 

4817

TERMINALIA SERICEA

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

Only for use when the plant part is root bark.

Only methanol/water (90:10; V/V) extract of Terminalia sericea bark of the root is approved.

The concentration in the medicine must be no more than 0.1%.

 

4818

TERPINEN-4-OL

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4819

TERPINEOL

E

 

4820

TERPINEOL ACETATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4821

TERPINOLENE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4822

TERPINYL ACETATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4823

TERPINYL BUTYRATE

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used as a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4824

TERPINYL METHYL ETHER

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4825

TERT-BUTYL ALCOHOL

E

Only for use in topical medicines for dermal application.

 

4826

TERT-BUTYL HYDROQUINONE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4827

TERT-BUTYL METHYL ETHER

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4828

TERT-BUTYLPYRAZINE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4829

TETRACLINIS ARTICULATA

A, E, H

 

4830

TETRADECYL AMINOBUTYROYLVALYLAMINOBUTYRIC UREA TRIFLUOROACETATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 0.002%.

 

4831

TETRADIUM RUTICARPUM

A, H

When for internal use, oxedrine is a mandatory component of Tetradium ruticarpum.

The quantity of oxedrine in the maximum recommended daily dose must be no more than 30 mg.

 

4832

TETRAHEXYLDECYL ASCORBATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 1%.

 

4833

TETRAHYDRO LINALYLACETATE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4834

TETRAHYDRO PARA-METHYLQUINOLINE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4835

TETRAHYDRO-6-(3-PENTENYL)-2H-PYRAN-2-ONE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4836

TETRAHYDRODIFERULOYLMETHANE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.1%.

 

4837

TETRAHYDROFURFURYL ACETATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4838

TETRAHYDROGERANYL ACETATE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4839

TETRAHYDROLINALOOL

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4840

TETRAHYDROMUGUOL

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4841

TETRAHYDROMYRCENOL

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4842

TETRAHYDROXYPROPYL ETHYLENEDIAMINE

E

Only for use in topical medicines for dermal application.

 

4843

TETRAMETHYL ACETYLOCTAHYDRONAPHTHALENES

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4844

TETRAPANAX PAPYRIFER

A, H

 

4845

TETRASODIUM ETIDRONATE

E

Only for use in topical medicines for dermal application.

 

4846

TETRASODIUM PYROPHOSPHATE

E

When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:

- (SODIUM) ‘The recommended daily dose of this medicine contains [state quantity and units] of sodium’ (or words to that effect).

 

4847

TEUCRIUM CHAMAEDRYS

A, H

The maximum recommended daily dose must be no more than 1mg of the equivalent dry herbal material of Teucrium chamaedrys.

 

4848

TEUCRIUM MARUM

A, H

The maximum recommended daily dose must be no more than 1mg of the equivalent dry herbal material of Teucrium marum.

 

4849

TEUCRIUM SCORODONIA

A, H

The maximum recommended daily dose must be no more than 1mg of the equivalent dry herbal material of Teucrium scorodonia.

 

4850

THAPSIA GARGANICA

A, H

 

4851

THAUMATIN

E

 

4852

THEASPIRANE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4853

THEMEDA TRIANDRA

A, H

 

4854

THEOBROMA CACAO

A, E, H

Caffeine is a mandatory component of Theobroma cacao.

When the route of administration is oral or sublingual and the medicine provides a maximum recommended daily dose of more than 1 mg but no more than 10 mg of caffeine in the medicine requires the following warning statement on the medicine label:

- (CAFFR) ‘The recommended dose of this medicine provides small amounts of caffeine.’

When the route of administration is oral or sublingual and the medicine provides a maximum recommended daily dose of more than 10 mg of caffeine in the medicine requires the following warning statement on the medicine label:

- (CAFF) ‘Contains caffeine [state quantity per dosage unit or per mL or per gram of product]’.

 

4855

THEOBROMA OIL

A, E, H

 

4856

THIAMINE

A, E

 

4857

THIAMINE HYDROCHLORIDE

A, E

 

4858

THIAMINE NITRATE

A, E

 

4859

THIOCINEOLE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4860

THIOTAURINE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.02%.

 

4861

THLASPI ARVENSE

A, E, H

 

4862

THREONINE

A, E

 

4863

THUJA OCCIDENTALIS

A, H

 

4864

THUJA PLICATA

A, E, H

 

4865

THYME HERB DRY

A, E, H

 

4866

THYME OIL

A, E, H

When the concentration of Thyme oil in the medicine is more than 50%, the nominal capacity of the container must be no more than 25 mL, a restricted flow insert must be fitted on the container and the medicine requires the warning statement:

- (CHILD) 'Keep out of reach of children' (or words to that effect).

 

4867

THYMOL

A, E

When used as an active ingredient, the medicine must be medicated space spray or medicated throat lozenges.

When used as an excipient, only for use in topical medicines for dermal applications.

 

 

4868

THYMUS CAPITATUS

A, E, H

When the plant preparation is an oil, and the concentration in the medicine is more than 50%, the nominal capacity of the container must be no more than 25 mL, a restricted flow insert must be fitted on the container and the medicine requires the following warning statement on the medicine label:

- (CHILD) 'Keep out of reach of children' (or words to that effect).

 

4869

THYMUS GLAND

H

Only for use as an active homoeopathic ingredient. 

 

4870

THYMUS MASTICHINA

A, E, H

When the plant preparation is an oil, and the concentration in the medicine is more than 50%, the nominal capacity of the container must be no more than 25 mL, a restricted flow insert must be fitted on the container and the medicine requires the following warning statement on the medicine label:- (CHILD) 'Keep out of reach of children' (or words to that effect).

 

4871

THYMUS SERPYLLUM

A, E, H

When the plant preparation is an oil, and the concentration in the medicine is more than 50%, the nominal capacity of the container must be no more than 25 mL, a restricted flow insert must be fitted on the container and the medicine requires the following warning statement on the medicine label:- (CHILD) 'Keep out of reach of children' (or words to that effect).

 

4872

THYMUS VULGARIS

A, E, H

When the plant preparation is oil or distillate, the nominal capacity of the container must be no more than 25 millilitres.

When the concentration of Thymus vulgaris oil or distillate in the preparation is greater than 50%, a restricted flow insert must be fitted on the container and the medicine must include the following warning statement on the medicine label:

- (CHILD) 'Keep out of reach of children' (or words to that effect)

 

4873

THYMUS VULGARIS MIS

A, E, H

When the plant preparation is an oil or distillate, the nominal capacity of the container must be no more than 25 millilitres.

When the concentration of  Thymus vulgaris mis oil or distillate in the preparation is greated than 50%, a restricted flow insert must be fitted on the container and the medicine must include the following warning statement on the medicine label:

- (CHILD) 'Keep out of reach of children' (or words to that effect)

 

4874

THYMUS ZYGIS

A, H

When the plant preparation is an oil or a distillate, the nominal capacity of the container must be no more than 25 millilitres.

When the concentration of Thymus zygis oil or distillate in the preparation is greater than 50%, a restricted flow insert must be fitted on the container and the medicine must include the following warning statement on the medicine label:

- (CHILD) 'Keep out of reach of children' (or words to that effect).

 

4875

TIGER SNAKE

H

Only for use as an active homoeopathic ingredient.

 

4876

TILACTASE

A

Must be derived from Aspergillus oryzae and comply with the relevant USP monograph.

When the dosage form is undivided, the units 'acid lactase units per gram' and 'Thousand acid lactase units per gram' are permitted.

When the dosage form is divided, the units 'acid lactase units' and 'thousand acid lactase units' are permitted.

 

4877

TILIA CORDATA

A, E, H

 

4878

TILIA PLATYPHYLLOS

A, E, H

 

4879

TILIA TOMENTOSA

A, H

 

4880

TILIA X VULGARIS

A, E, H

 

4881

TILIANTOL

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4882

TIN

H

Only for use as an active homoeopathic ingredient. 

 

4883

TINOSPORA CORDIFOLIA

A, H

 

4884

TINOSPORA SINENSIS

A, H

 

4885

TITANIUM DIOXIDE

A, E

For use as an active ingredient only in sunscreens for dermal application.

The concentration in sunscreens must be no more than 25%.

For use as an excipient only as a colour in oral medicines and as a colour in topical medicines for dermal application.

Not to be included in medicines intended for use in the eye.

When used in primary sunscreen products and listed in the Register on or after 1 January 2018, the medicine must have the following statements on the medicine label:

- (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and

- (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).

When used in primary sunscreen products and listed in the Register before 1 January 2018, the medicine requires the following statements on the medicine label if supplied after 1 July 2019:

- (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and

- (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).

 

 

4886

TOCOCYSTEAMIDE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.01%.

 

4887

TOCOFERSOLAN

E

Only for oral and topical use.

When for oral use, the concentration in the medicine must be no more than 10% w/w.

When used in topical medicines for dermal application, it is not to be included in medicines intended for use in the eye.

When for topical use, the concentration in the medicine must be no more than 0.1%

 

4888

TOCOPHEROL

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4889

TOCOPHERYL GLUCOSIDE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use on damaged skin or in the eye.

The concentration in the medicine must be no more than 0.05%

 

 

4890

TOCOPHERYL LINOLEATE

E

Only for use in topical medicines for dermal application.

 

4891

TOCOPHERYL NICOTINATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration must not exceed 0.3%.

 

4892

TOLU BALSAM

A, E, H

 

4893

TOLUENE

E

The residual solvent limit for toluene is 8.9 mg per maximum recommended daily dose.

The concentration in the medicine must be no more than 0.089%.

 

4894

TOLYL ALDEHYDE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4895

TOLYLALDEHYDE GLYCERYLACETAL

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4896

TOMATO

E

 

4897

TONKA

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4898

TONKA BEAN EXTRACT

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4899

TONONE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4900

TOXICODENDRON DIVERSILOBUM

H

Only for use as an active homoeopathic ingredient. 

 

4901

TOXICODENDRON PUBESCENS

H

Only for use as an active homoeopathic ingredient.

The maximum recommended daily dose must be no more than 1mg of the equivalent dry herbal material of Toxicodendron pubescens.

 

 

4902

TOXICODENDRON RADICANS

A, H

The maximum recommended daily dose must be no more than 1mg of the equivalent dry herbal material of Toxicodendron radicans.

 

4903

TOXICODENDRON SUCCEDANEUM

H

Only for use as an active homoeopathic ingredient. 

 

4904

TRACHELOSPERMUM JASMINOIDES

A, E, H

 

4905

TRACHYSPERMUM AMMI

A, E

Only for use in oral medicines when the plant part is fruit or seed.

The medicine requires the following warning statements on the medicine label:

- (PREGNT) 'Not recommended for use by pregnant and lactating women' (or words to that effect)

- (PREGNT2) 'Do not use if pregnant or likely to become pregnant' (or words to that effect).

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4906

TRAGACANTH

A, E

 

4907

TRAMETES VERSICOLOR

A, H

 

4908

TRAMETES VERSICOLOR PROTEOGLYCAN CONCENTRATE

A, H

Only for use in oral medicines.

 

4909

TRANS,TRANS-2,4-DECADIEN-1-AL

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4910

TRANS,TRANS-2,4-HEXADIENAL

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in the medicine must be no more than 1%.

The maximum daily dose must provide no more than 13.5 mg of Trans,Trans-2,4-Hexadienal.

 

4911

TRANS-1-(2,4,4-TRIMETHYL-2-CYCLOHEXEN-1-YL)-2-BUTEN-1-ONE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4912

TRANS-2-DECENAL

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4913

TRANS-2-DODECENAL

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4914

TRANS-2-HEPTEN-1-AL

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4915

TRANS-2-HEXENAL

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4916

TRANS-2-HEXENOIC ACID

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4917

TRANS-2-HEXENOL

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

 

4918

TRANS-2-HEXENYL ACETATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4919

TRANS-2-HEXENYL PHENYLACETATE

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4920

TRANS-2-HYDROXYCINNAMIC ACID

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4921

TRANS-2-UNDECENAL

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4922

TRANS-3-HEXENOIC ACID

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4923

TRANS-4-DECENAL

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4924

TRANS-8-(1-METHYLETHYL)-1-OXASPIRO(4.5)DECAN-2-ONE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4925

TRANS-ETHYL 2-OCTENOATE

E

Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4926

TRANS-METHYL-2-HEXENOATE

E

Permitted for use only in combination with other permitted ingredients as a flavour.

If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

 

4927

TREACLE

E

When for oral or sublingual use, sucrose is a mandatory component of Treacle.

When the medicine is for oral ingestion and the total amount of all sugars (monosaccharides and disaccharides such as glucose, honey, invert sugar, lactose, maltose, and sucrose) is more than 100mg in the maximum daily dose, then the medicine requires the following warning statement on the medicine label:

- (SUGARS) ‘Contains [insert name of sugar]’ if medicine contains one sugar OR ‘Contains sugars' (or words to that effect) if medicine contains two or more sugars.

If one of the sugars is lactose then the medicine also requires the following warning statement on the medicine label:

- (LACT) ‘Contains lactose' (or words to that effect).

 

4928

TREEMOSS ABSOLUTE

E

Permitted for use only in combination with other permitted ingredients as part of a fragrance proprietary excipient formulation.

When included in a medicine for use on the lips the concentration of treemoss absolute must be no more than 0.02%.

When for dermal use or use on the hair the concentration of treemoss absolute must be no more than 0.1%

The total fragrance proprietary excipient formulation in a medicine must be no more than 1%.

 

4929

TREFRIW WELLS MINERAL WATER

A

When for internal use, iron is a mandatory component of Trefriw Wells mineral water.

Solid dosage forms containing more than 5 milligrams of elemental iron in each dosage unit are required to have a child resistant closure.

Liquid Preparations containing more than 250 milligrams of elemental iron in the total contents of the container are required to have a child resistant closure.

Only able to be used when presented in single use sachets for therapeutic use as an iron supplement.

 

4930

TREHALOSE DIHYDRATE

E

When for oral use and the quantity of trehalose dihydrate per maximum recommended daily dose exceeds 20 grams, the quantity of trehalose dihydrate must be declared on the label.

 

4931

TREMELLA FUCIFORMIS

A, H

 

4932

TRIACETIN

E

 

4933

TRIACONTANYL PVP

E

Only for use in topical medicines for dermal application.

 

4934

TRIADICA SEBIFERA

A, H

 

4935

TRIBASIC POTASSIUM PHOSPHATE

A, E, H

When used as an active ingredient and the medicine is intended as a mineral supplementation, potassium is a mandatory component of tribasic potassium phosphate.

When used in a solid medicine containing this ingredient, the pH of a 10 g/L aqueous solution must not be more than 11.5.

When used in a liquid or a semi-solid medicine containing this ingredient, the pH of the medicine must be no more than 11.5.

 

4936

TRIBASIC SODIUM PHOSPHATE

E

When used in a solid preparation, the pH of a 10 g/L aqueous solution must not be more than 11.5.

When used in a liquid or a semi-solid preparation, the pH of the preparation must not exceed 11.5.

When for oral or sublingual use and the total amount of sodium from all ingredients in the maximum daily dose is more than 120 mg, the medicine requires the following warning statement on the medicine label:

- (SODIUM) ‘The recommended daily dose of this medicine contains [state quantity and units] of sodium’ (or words to that effect).

 

4937

TRIBEHENIN

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 6%.

 

4938

TRIBEHENIN PEG-20 ESTERS

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 6%.

 

4939

TRIBULUS TERRESTRIS

A, E, H

 

4940

TRIBUTYL ACETYLCITRATE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4941

TRICALCIUM PHOSPHATE

E

 

4942

TRICAPRYLIN

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 5%.

 

4943

TRICAPRYLYL CITRATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 7%.

 

4944

TRICETEARETH-4 PHOSPHATE

E

Only for use in topical medicines for dermal application.

 

4945

TRICHLOROMETHYLPHENYLCARBINYL ACETATE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4946

TRICHODERMA VIRIDE

A, E, H

 

4947

TRICHOSANTHES KIRILOWII

A, E, H

 

4948

TRICLOSAN

E

The concentration in the medicine must be no more than 1%.

 

 

4949

TRICYCLODECENYL PROPIONATE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4950

TRIDECANAL

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4951

TRIDECETH-4 PHOSPHATE

E

Only for use in topical medicines for dermal application.

 

4952

TRIDECETH-6

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 0.5%.

 

4953

TRIDECYL ALCOHOL

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used as in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4954

TRIDECYL BEHENATE

E

Behenic acid is a mandatory component of Tridecyl behenate.

Only for use in topical medicines for dermal application.

 

4955

TRIDECYL NEOPENTANOATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 23%.

 

4956

TRIDECYL SALICYLATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. 

The concentration in the medicine must be no more than 5%.

 

4957

TRIDECYL STEARATE

E

Only for use in topical medicines for dermal application.

 

4958

TRIDECYL TRIMELLITATE

E

Only for use in topical medicines for dermal application.

 

4959

TRIETHOXYCAPRYLYLSILANE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 1%.

 

4960

TRIETHYL CITRATE

E

 

4961

TRIETHYLENE GLYCOL

E

 

4962

TRIFOLIUM PRATENSE

A, E, H

 

4963

TRIFOLIUM REPENS

A, H

 

4964

TRIGONELLA FOENUM-GRAECUM

A, E, H

 

4965

TRIHYDROXYPALMITAMIDOHYDROXYPROPYL MYRISTYL ETHER

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.02%.

 

4966

TRIHYDROXYSTEARIN

E

Only for use in topical medicines for dermal application.

 

4967

TRIISOCETYL CITRATE

E

Only for use in topical medicines for dermal application.

 

4968

TRIISODECYL TRIMELLITATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 5%.

 

4969

TRIISONONANOIN

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 5%.

 

4970

TRIISOSTEARIN

E

Only for use in topical medicines for dermal application.

 

4971

TRILAURIN

E

Only for use in topical medicines for dermal application.

 

4972

TRILISA ODORATISSIMA

A, H

 

4973

TRILLIUM ERECTUM

A, H

 

4974

TRIMETHOXYCAPRYLYL SILANE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.25%.

 

4975

TRIMETHYL HYDROXYPENTYL ISOBUTYRATE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4976

TRIMETHYL UNDECYLENIC ALDEHYDE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4977

TRIMETHYL-BICYCLO-HEPTANE-SPIROCYCLOHEXENONE

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4978

TRIMETHYLBENZENEPROPANOL

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4979

TRIMETHYLHEXANOL

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4980

TRIMETHYLOPROPANE TRIOCTANOATE

E

Only for use in topical medicines for dermal application.

 

4981

TRIMETHYLPENTANEDIOL/ADIPIC ACID/GLYCERIN CROSSPOLYMER

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 5%.

 

4982

TRIMETHYLSILOXYSILICATE

E

Only for use in topical medicines for dermal application.

 

4983

TRINITROPHENOL

H

Only for use as an active homoeopathic ingredient. 

 

4984

TRIOCTANOIN

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 5%.

 

4985

TRIOCTYLDODECYL CITRATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 12%.

 

4986

TRIOLEIN

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.1%.

 

4987

TRIOSTEUM PERFOLIATUM

A, H

 

4988

TRIOXAUNDECANEDIOIC ACID

E

 

4989

TRIPAL

E

Permitted for use only in combination with other permitted ingredients as a fragrance.

If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

 

4990

TRIPEPTIDE-1

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on damaged skin.

The concentration in the medicine must be no more than 0.002%.

 

4991

TRIS-BIPHENYL TRIAZINE

A

Only for use as an active ingredient in sunscreens for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 10%.

When used topically, the dosage form must not be spray.

When used in primary sunscreen products and listed in the Register on or after 1 January 2018, the medicine must have the following statements on the medicine label:

- (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and

- (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).

When used in primary sunscreen products and listed in the Register before 1 January 2018, the medicine requires the following statements on the medicine label if supplied after 1 July 2019:

- (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and

- (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).

 

4992

TRISILOXANE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 40%.

 

4993

TRISODIUM EDETATE

E

Only for use in topical medicines for dermal application.

 

4994

TRISODIUM ETHYLENEDIAMINE DISUCCINATE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.2%.

 

4995

TRISODIUM NTA

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.005%.

 

4996

TRISTEARIN

E

 

4997

TRITICUM AESTIVUM

A, E, H

Gluten is a mandatory component when the plant part is seed and the route of administration is other than topical and mucosal.

When the route of administration is other than topical or mucosal, the medicine requires the following warning statement on the medicine label:

- (GLUTEN) 'Contains [insert name of ingredient]' (or words to that effect).

 

4998

TRITICUM DURUM

A, E, H

Gluten is a mandatory component when the plant part is seed and the route of administration is other than topical and mucosal.

When the route of administration is other than topical or mucosal, the medicine requires the following warning statement on the medicine label:

- (GLUTEN) 'Contains [insert name of ingredient]' (or words to that effect).

 

4999

TRIUNDECANOIN

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 11.2%.

 

5000

TROLAMINE

E

Only for use in topical medicines for dermal application.

The concentration in the medicine must be no more than 5%.

 

5001

TROLAMINE LAURIL SULFATE

E

Only for use in topical medicines for dermal application.

 

5002

TROLAMINE SALICYLATE

A

Only for use as an active ingredient in sunscreens for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 12%.

When used in primary sunscreen products and listed in the Register on or after 1 January 2018, the medicine must have the following statements on the medicine label:

- (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and

- (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).

When used in primary sunscreen products and listed in the Register before 1 January 2018, the medicine requires the following statements on the medicine label if supplied after 1 July 2019:

- (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and

- (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).

 

5003

TROLLIUS CHINENSIS

A, H

 

5004

TROMETAMOL

E

 

5005

TROMETAMOL HYDROCHLORIDE

E

 

5006

TROPAEOLUM MAJUS

A, E, H

 

5007

TROPICAL RATTLESNAKE

H

Only for use as an active homoeopathic ingredient.

 

5008

TROPOLONE

E

Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.

The concentration in the medicine must be no more than 0.01%.

 

5009

TSUGA CANADENSIS

A, H

 

5010

TULIPA EDULIS

A, H

Colchicine is a mandatory component of Tulipa edulis.

The concentration of colchicine in the medicine must be no more than 10 mg/kg or 10 mg/L or 0.001%.

 

5011

TURMERIC

E

Permitted for use only in combination with other permitted ingredients as a colour.

 

5012

TURNERA DIFFUSA

A, E, H

Arbutin is a mandatory component of Turnera diffusa.

The concentration of arbutin in the medicine must be no more than 25 mg/Kg or 25mg /L or 0.0025 % unless used on the hair.

When for use on hair, the concentration of arbutin in the medicine must be no more than 0.74 %.

 

5013

TURNIP

E

 

5014

TURPENTINE OIL

A, E

The concentration in the medicine must be no more than 25%.

 

5015

TYPHA ANGUSTIFOLIA

A, H

 

5016

TYPHA LATIFOLIA

A, H

 

5017

TYPHONIUM GIGANTEUM

A, H

 

5018

TYROSINE

A, E